

Making adherence part of their daily lives



Effective phosphate management, simplified

물과 함께 복용할 필요 없이 소량의 부드러운 음식에 섞어서 복용합니다.
정제를 씹거나 삼키기 어려운 환자도 쉽게 복용할 수 있습니다.¹

Ref) 1. FOSRENOL Summary of Product Characteristics, December 2014

포스레놀 정 FOSRENOL Tab 포스레놀 산 FOSRENOL Oral Powder
[성분 및 함량] Lanthanum carbonate 954mg(포스레놀정500mg), 1431mg(포스레놀정 750mg), 1908mg(포스레놀산1000mg) [효능효과] 혈액투석이나 복막투석을 받는 만성신부전 환자의 고인산혈증 치료 [용법용량] 정제의 경우 이 약을 그대로 삼키지 않고 반드시 씹어서 복용해야 한다. 씹는 것을 용이하게 하기 위해 이 약을 부수어 복용할 수 있다. 이 약을 처음 복용하는 환자는 혈청 인산 농도에 따라, 다음과 같은 초기 투여량을 매 식사와 함께 혹은 식후 즉시 분복한다. 산제의 경우, 이 약을 소량의 부드러운 음식에 섞어서 즉시 복용해야 한다. (15분 이내) 이 약 투여 전에 약포를 미리 개봉해서는 안 된다. 또한 다음번 투여를 위해 이 약을 음식과 미리 섞어서 보관해서는 안 된다. 이 약은 녹지 않으므로 복용을 위해 액체에 녹이지 않는다. 포스레놀 초기 투여량, 혈청 인 5.6~7.4mg/dL의 경우 일일 750mg, 7.4~9.0mg/dL의 경우 일일 1500mg, 9.0mg/dL이상의 경우 일일 2250mg의 용량을 투여한다. 규칙적으로 혈청 인산 농도를 모니터링하면서 적정 혈청 인산농도에 도달할 때까지 2~3주 간격으로 투여량을 조정한다. 혈청 인산 농도는 란탄으로서 750mg/일 용량에서 조절되기 시작하였고, 대부분의 환자에서 1500~3000mg/일 용량에서 적정 혈청 인산농도에 조절되었다. 환자들은 인산이나 물의 섭취량을 조절하기 위해 권장된 식이요법을 준수해야 한다. 복용 시 물을 복용할 필요는 없다. [사용상 주의사항 및 금기] 제품설명서 참조 [이상반응] 가장 흔하게 보고된 이상반응은 위장관계 증상이었다. 위장관계 증상은 이 약을 식사와 함께 투여 시 발생빈도가 최소화되고, 일반적으로 투여가 지속될수록 약해진다.
※ 보다 자세한 내용은 홈페이지나 제품설명서를 참고하시기 바랍니다.

KOR/C-APROM/FOS/16/0002



제이더블유중외제약
고객만족팀 : 1588-2675, www.jw-pharma.co.kr
서울시 서초구 남부순환로 2477(구·서초동 1424-2) JW타워
제품에 대한 상세한 내용은 제품 설명서나 본사 홈페이지를 참조하시기 바랍니다.




칼세파라 | Calcepara

Cost effective calcimimetic for Secondary Hyperparathyroidism

칼세파라 투석 환자의 효과적인 부갑상선기능항진증 치료를 위한 칼슘유사체

칼세파라는 iPTH 농도¹ 및 부갑상선 용적을 감소시켜² 부갑상선절제술³을 유의하게 감소시켰습니다.
또한, 투석 환자의 사망위험 감소⁴, 빈혈 조절⁵, 골절 예방⁶에도 도움을 줄 수 있습니다.
칼세파라는 효과적인 이차성 부갑상선기능항진증 치료제입니다.¹⁻⁶



참고문헌

1. Wetmore et al, A randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015;10:1031-1040
2. Komaba H et al, Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2010 Dec;5(12):2305-14
3. Palmer SC et al, Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med. 2013;10(4):e1001436. doi: 10.1371
4. Akizawa T et al, PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep. 2016 Apr 13;6:19612. doi: 10.1038/srep19612
5. Torun D et al, The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary hyperparathyroidism. Saudi J Kidney Dis Transpl. 2016;27(1):15-22
6. Moe SM, Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE Trial. J Am Soc Nephrol. 2015 Jun;26(6):1466-75

‘투석 시작’ 시기를 지연시키는 신부전 진행억제제¹

씨제이 **크레메진**[®] 세립
KREMEZIN

투석 시작 시기 지연¹

요독증 개선 및 완화²

QOL 향상³

사회·경제적 이득효과³

CJ HealthCare 서울시 중구 동호로 330 CJ제일제당센터 11층, 12층 / 고객센터: 080.700.8802 / www.cjp.co.kr

제품정보 - 【성분 함량】 kremezin 2g 【효능 효과】 만성신부전증(진행성)에 대한 요독증 증상의 개선 및 투석도입의 지연 【용법 용량】 성인 1일 3회, 1회 2그램(1포) 복용 【사용상의 주의사항】 및 기타 자세한 내용은 제품설명서를 참조하시기 바랍니다.
References - 1. The Journal of International Medical Research 2009;37(1):1-9 2. Clinical Evaluation 1987;15(3):527-564 3. Nephrology 2008;13:419-427

The Right Key

to High Bleeding Risk Patients
in HD & CRRT!



HD: hemodialysis, CRRT: continuous renal replacement therapy

후탄은 출혈성 병변 및 출혈경향을 갖는 환자의
혈액체외순환 시 사용할 수 있는 **항응고제**입니다.¹

- 반감기가 짧아(5~8분) 항응고작용이 체외순환로에 국한됩니다.^{2,3}
- 출혈 위험이 있는 환자의 HD 시 출혈 위험도를 증가시키지 않습니다.^{4,5}
- CRRT 시행 시 filter-life를 유의하게 연장시킵니다.^{6,7}



전문약품 분류번호 : 399

제품요약정보

【제품명】 주사용후탄(나파모스타트메실산염) • 주사용후탄50(나파모스타트메실산염) 【원료약품 및 그 분량】 주사용후탄 1 바이알 중 주성분 : 나파모스타트메실산염(JP) 10mg • 주사용후탄50 1 바이알 중 주성분 : 나파모스타트메실산염(JP) 50mg 【효능·효과】 1. 혈액의 급성응고(급성혈액, 만성혈액의 급성 악화기, 수술후의 급성혈액, 체관조영술 후의 급성혈액, 외상성 혈액)의 개선 - 주사용후탄 10mg만 해당 2. 파종혈관내응고증(DIC) 3. 출혈성 병변 및 출혈경향을 갖는 환자의 혈액체외순환시 관류혈액 응고방지(혈액투석 및 혈장분리반출술 【용법·용량】 가. 투여방법 (중략) 3. 출혈성 병변 및 출혈경향을 갖는 환자의 혈액체외순환시 관류혈액 응고방지 보통 체외순환개시에 앞서 나파모스타트메실산염으로서 20mg을 소량의 5% 포도당주사액이나 주사용수에 용해한 후 생리식염액 500mL에 용해한 액으로 혈액회로내를 세정·충진하고 체외순환개시 후에는 나파모스타트메실산염으로서 매시 20~50mg을 5% 포도당주사액에 용해하여 항응고제 주입라인에 지속주입한다. 증상에 따라 적의 증감한다. 임상결과에서는 평균 투여용량이 매시간 35mg이었다. (생략) 【제조·유통】 에스케이케미칼(주) 【제조사】 유한양행 충북 청원군 오창읍 연구단지 219 / Tel. 02-828-0181 • (주)펜믹스 충남 천안시 서북구 직산읍 거리막길 33 / Tel. 02-703-8234 ※ 처방하기 전 제품설명서 전문을 참고하십시오. 최신 허가사항에 대한 정보는 '온라인의약품도서관(http://drug.mfds.go.kr)'에서 확인할 수 있습니다.

References 1. 주사용후탄 허가정보, 온라인의약품도서관 [Cited 2016 Nov 04]. Available from: http://drug.mfds.go.kr 2. 秋沢忠男 et al, 腎と透析, 1989;26(5):145-51. 3. H. Hirasawa, 総合腎学, 1998;p.25-30. 4. Kim HC et al, Korean J Nephrol, 2004;23(6):920-6. 5. Akizawa T et al, Artificial Organs, 1991;14:209-12. 6. Choi et al, Medicine, 2015;94(52):e2392. 7. Hwang SD et al, Int J Artif Organs, 2013 ;36(3):208-16 8. Akizawa T et al, Nephron, 1993;64(3):376-81 9. Lee YK et al, PLoS One, 2014 Oct 10;9(10):e108737.

SK 케미칼
Life Science Biz.

경기도 성남시 분당구 판교로 310(삼평동) Tel 080-021-3131 www.skchemicals.com/ls

Slow ADPKD. Preserve Hope.

Introducing Samsca — The first and only treatment proven to slow cyst progression



삼스카®정 ADPKD 허가사항 (저나트륨혈증 관련 허가사항은 제품설명서 참고 부탁드립니다.) [효능효과] 최초 투여시 만성신질환 1~3 단계에 해당되며, 빠르게 진행되고 있는 상염색체우성 다낭신장병(ADPKD, autosomal dominant polycystic kidney disease) 성인 환자에서의 낭종 생성 및 신기능 저하 진행의 지연 [용법·용량] 상기 효능효과에 처방시, 이 약은 위해관리프로그램에 등록된 의사만이 처방할 수 있으며, 이 프로그램에서 정하고 있는 사항에 동의하고, 서명한 환자에 한하여 처방할 수 있다. 환자들은 이 프로그램을 준수하여야 한다. 또한, 심각한 비가역적 간손상의 위험을 감소시키기 위하여 이 약의 최초 투여 개시 전에 ALT 및 AST 와 총빌리루빈에 대한 혈액검사가 필요하며, 투여기간 첫 18 개월 동안은 매월, 그 이후에는 3 개월에 한 번씩 간기능 검사를 반드시 실시한다. 초기용량 아침 식전 45mg, 8 시간 이후 15mg 1 주일 이상 간격 두고 증량 아침 식전 60mg, 8 시간 이후 30mg 목표용량 아침 식전 90mg, 8 시간 이후 30mg ※ 자세한 용법과 CYP3A 억제제 병용시 감량 및 주의사항은 제품설명서 참고부탁드립니다.

REGPARA®

Cinacalcet HCl 25mg

The Ideal Treatment for *SHPT*



☑ iPTH

☑ Calcium


☑ Phosphorus

☑ Calcium x Phosphorus

제품개요

레그파라의 주성분인 시나칼세트는 칼슘유사작용성 화합물(Calcimimetics) 제제로서 부갑상선 주세포 표면에서 세포외 칼슘에 대한 칼슘 감지 수용체의 민감도를 증가시켜 부갑상선호르몬(PTH) 분비를 직접적으로 감소시켜 줍니다. 시나칼세트의 분자식은 $C_{21}H_{25}FN \cdot HCl$ 로서 분자량은 염산염으로서 393.9g/mol입니다. 구조 중에(R) 절대배열(absolute configuration)을 가진 한 개의 키랄 중심(chiral center)이 있고, 광학이성질체로서는 R형이 강력하며 약리작용면에서도 주요한 역할을 담당합니다.

조성·성상

제명명	레그파라정 25mg
유효성분	1정 중 시나칼세트 염산염 27.55mg (시나칼세트로서 25mg)
색·재형	담녹색~담황녹색의 필름코팅정
외형	앞면  뒷면  측면 

효능·효과

투석을 받고 있는 만성신부전 환자와 관련된 이차성 부갑상선 기능 항진증의 치료

용법·용량

본 약제의 경우투여시, 분할하여 복용하지 않습니다. 개시 용량으로서, 성인에게는 1일 1회 시나칼세트로서 25mg을 경구 투여합니다. 이후는, 환자의 부갑상선 호르몬(PTH) 및 혈청 칼슘 농도를 모니터링하면서 혈청 칼슘치 또는 부갑상선호르몬(PTH)을 기준으로, 1일 1회 25, 50, 75mg으로 용량을 조정하여, 경구 투여합니다. 다만, 부갑상선호르몬(PTH)의 개선이 확인되지 않는 경우에는, 1회100mg을 상한으로서 경구 투여합니다. 중량을 실시하는 경우는 증량폭을 25mg로 하여, 3주간 이상의 간격을 두고 실시합니다.

- 이약은 혈중 칼슘의 저하 작용을 가지므로, 혈청 칼슘치가 낮지 않은 것(기준으로서 9.0mg/dL 이상)을 확인하고 투여를 개시해야 합니다.
- 혈청 칼슘치는, 본 약제의 개시시 및 용량 조정시는 주 1회 측정하고, 유지기에는 2주에 1회이상 측정하고, 혈청 칼슘치가 8.4mg/dL 미만으로 낮아졌을 경우는, 아래 표와 같이 대응해야 합니다.

혈청칼슘치	처치		대응	
	저	치	검사	증량·재개
8.4mg/dL 미만	본 약제의 투여를 중단하고, 2주에 1회이상 측정한다. (필요시 본 약제를再開합니다.)	칼슘제나 비타민 D제와의 투여를 고려합니다.	중량혈장투여를 주1회이상 실시한다. 이상으로 회복된 것을 확인후, 동량투여한다.	중량혈장투여는 8.4mg/dL 이상으로 회복된 것을 확인후, 투여량에 동량투여나 그 이하로 재개하십시오.
7.5mg/dL 미만	즉시 중단합니다.			

혈청 칼슘치의 검사는, 본제의 약효 및 안전성을 적절하게 판단하기 위해서, 복용전에 실시하는 것이 바람직합니다. 또, 저알부민혈증(혈청알부민치가 4.0 g/dL 미만)의 경우에는, 보정치를 지표로 이용하는 것이 바람직합니다. 보정 칼슘치 산출 방법: 보정 칼슘치(mg/dL) = 혈청 칼슘치(mg/dL) - 혈청알부민치(g/dL) + 4.0 (Guidelines for the management of secondary hyperparathyroidism in chronic dialysis patients, 39,10(2006):1440)

사용상의 주의사항

- 경고
 - 경련발작: 해외 임상시험에서, 경련 발작의 병력이 있는 환자등에서 경련 발작이 발현했다는 보고가 있습니다.
- 저혈압 및 심부전 악화: 외국의 시판후 조사에서 심부전 환자에서 저혈압 및 심부전 악화가 보고되었으며, 이 부작용은 이 약과의 상관성을 배제할 수 없으며, 혈중 칼슘 농도 감소에 의한 것으로 여겨집니다. 임상시험 결과는 이 약 투여환자의 7%와 위약 투여 환자의 12%에서 저혈압이 발생하였으며, 심부전은 이 약 또는 위약 투여 환자의 2%에서 발생하였습니다.

Title	The 37 th Annual Meeting of the Korean Society of Nephrology (KSN2017)
Date	May 18 - 21, 2017
Venue	Convention Centre, Grand Hilton Hotel, Seoul, Korea
Hosted by	The Korean Society of Nephrology, The Research Institute of Kidney Disease
Language	Korean, English
Program	Opening Ceremony, Welcome Reception, Scientific Session, Gala Dinner, Exhibition
Contact	The Korean Society of Nephrology #1401, 42, Seocho-daero 78-gil, Seocho-gu, Seoul, Korea, 06626 Tel. 82-2-3486-8736 Fax. 82-2-3486-8737 Email. ksn@ksn.or.kr KSN 2017 Secretariat (c/o MCI Korea) Busung Bldg 3F, 9 Nonhyeon-ro 21-gil, Gangnam-gu, Seoul, Korea, 06237 Tel. +82-2-6263-2054 Fax.+82-2-579-2662 Email. office@ksnmeeting.kr

The Korean Society of Nephrology Organization

Organizing Committee

President	Yong-Soo Kim, M.D.	Director, the Insurance and Legal Affairs	Byoung Geun Han, M.D. Seong Nam Kim, M.D.
Congress President	Yong-Lim Kim, M.D.	Treasurer	Duk-Hee Kang, M.D.
Congress Vice-President	In Seok Lim, M.D.	Director, the Ethical Issues	JongSoo Lee, M.D.
Auditor	Yeong Hoon Kim, M.D.	Director, the Public Relation	Sang Kyung Jo, M.D.
Secretary General	Seok Joon Shin, M.D.	Director, the Dialysis Quality Assurance	Kwon Wook Joo, M.D. Jung Geon Lee, M.D.
Vice-Secretary General	Dong Ki Kim, M.D. Hye Eun Yoon, M.D.	Director, the Planning	Cheol Whee Park, M.D.
Director, the Scientific Programs	Dae Ryong Cha, M.D.	Director, at Large	Seung Jung Kim, M.D. Chan-Duck Kim, M.D. Eun Young Lee, M.D. Seung-Yeup Han, M.D. Soo Bong Lee, M.D.
Director, Committee of External Affairs and Cooperation	Hyeong Cheon Park, M.D.		
Director, the Training and Education	Ki Young Na, M.D.		
Director, the Publication	Soo Wan Kim, M.D.		
Director, the ESRD Registry	Dong Chan Jin, M.D.		

Scientific Committee


Director	Dae Ryong Cha, M.D.	
Committee Members	Young Sun Kang, M.D.	Eun Hui Bae, M.D.
	Hee Gyung Kang, M.D.	Joon Ho Song, M.D.
	Jeong-Hae Kie, M.D.	Wonsuk An, M.D.
	Beom Seok Kim, M.D.	Dong Jin Oh, M.D.
	Sung Gyun Kim, M.D.	So Young Lee, M.D.
	Won Kim, M.D.	Ji Eun Lee, M.D.
	Hyosang Kim, M.D.	Kyung Hwan Jeong, M.D.
	Hyunjin Noh, M.D.	De Eun Choi, M.D.
	Sun-Hee Park, M.D.	Sang-Youb Han, M.D.

Dear Colleagues and Friends,


It is our great honor and pleasure to invite you to the 37th Annual Meeting of the Korean Society of Nephrology (KSN 2017) in Seoul, Korea on May 18-21, 2017.

One of the major missions of KSN is to provide various educational opportunities and promote international exchanges for the society members. Since the foundation in 1981, KSN has organized national scientific meetings and expanded the 36th annual meeting of KSN as an international gathering. More than 1,800 kidney professionals attended at the KSN 2016, and 42 overseas experts were invited to give engaging lecture and provocative discussion. KSN 2017 is to be held as a second international meeting and we are anticipating it will be a more flourished one than last year. We are planning inspiring events featuring some of the world's most renowned professionals in the field, key opinion leaders in the global nephrology community, distinguished keynote speakers, and panelists to share their experiences and exchange knowledge. We also aim to create a warm event where we can socialize with as many people as possible, and build a strong networking with each other.

We encourage you to actively participate in and enjoy this fascinating opportunity by sharing your valuable expertise and experiences with top-notch researchers from all over the world.




Ki myungsoo
Yong-Soo Kim, M.D.
President,
The Korean Society of
Nephrology




Yonglim Kim
Yong-Lim Kim, M.D.
Congress President,
The Korean Society of
Nephrology


Convention Centre 4F / Grand Ballroom 2F



Convention Centre 3F



Convention Centre 1F



KSN 2017 Program at a glance

KSN 2017 Program at a glance

Korean Session

May 18(Thur)						
Room Time	Room 1 Convention Hall 1,2 (4F)	Room 2 Convention Hall 3 (4F)	Room 3 Diamond Hall (3F)	Room 4 Emerald Hall (2) (3F)	Room 5 Emerald Hall (1) (3F)	Grand Ballroom Hotel (2F)
12:00 - 13:20	Registration					
13:20 - 13:30	Opening Ceremony					
13:30 - 14:20	Plenary Lecture I					
14:30 - 16:30	Nephrology Education	Basic Renal Pathology	Acute Kidney Injury	Geriatric Nephrology	Hypertension & Vascular Biology	
16:30 - 18:30	Nephrology Education	Hemodiafiltration	Glomerular & Tubulointerstitial Disease	Fluid, Electrolyte & Acid-Base	Diabetes & Obesity	
19:00 - 21:00						Welcome Reception

May 19(Fri)						
Room Time	Room 1	Room 2	Room 3	Room 4	Room 5	Grand Ballroom
	Convention Hall 1,2 (4F)	Convention Hall 3 (4F)	Diamond Hall (3F)	Emerald Hall (2) (3F)	Emerald Hall (1) (3F)	Hotel (2F)
07:30-08:30	Registration					
08:30-09:20	Plenary Lecture II					
09:30-10:00	Coffee Break & Poster Visit					
10:00-12:00	Diabetes & Obesity	Chronic Kidney Disease	Inherited Kidney Disease	Peritoneal Dialysis	Hemodialysis	
12:00-13:00	Luncheon Symposium					
13:00-14:00	Coffee Break & Poster Visit					
14:00-15:00	Oral Presentation 1 Acute Kidney Injury	Oral Presentation 2 Chronic Kidney Disease	Oral Presentation 3 Diabetes & Obesity	Oral Presentation 4 Dialysis	Oral Presentation 5 Transplantation	Kidney Academy Course
15:00-16:00	Poster Visit & Poster Presentation					
16:00-18:00	Transplantation	Hemodialysis	Nutrition, Inflammation & Metabolism	Bone & Mineral Disease	Acute Kidney Injury	
18:30-20:30						Gala Dinner

Korean Session

May 20(Sat)						
Room Time	Room 1	Room 2	Room 3	Room 4	Room 5	Grand Ballroom
	Convention Hall 1,2 (4F)	Convention Hall 3 (4F)	Diamond Hall (3F)	Emerald Hall (2) (3F)	Emerald Hall (1) (3F)	Hotel (2F)
07:00 - 07:30						KSN Board of Regent
07:30 - 08:00	Registration					
08:00 - 08:30	Plenary Lecture III					
08:30 - 08:50						
09:00 - 10:00	Oral Presentation 6 Chronic Kidney Disease	Oral Presentation 7 Glomerular & Tubulointerstitial Disease	Oral Presentation 8 Transplantation	Oral Presentation 9 Geriatric Nephrology	Oral Presentation 10 Hypertension & Vascular Biology	
10:00 - 11:30	Basic Science Session Microbiome	Basic Science Session Bioinformatics & Systems Biology	Basic Science Session Transporters and Channels	Basic Science Session Regulatory RNA	Basic Science Session Genomic Editing	Ethics Education
11:30 - 12:30	Luncheon Symposium					
12:30 - 13:30	General Assembly(Award)	Poster Visit & Poster Presentation				
13:30 - 14:30	Oral Presentation 11 Chronic Kidney Disease	Oral Presentation 12 Dialysis	Oral Presentation 13 Transplantation	Oral Presentation 14 Nutrition & Inflammation	Oral Presentation 15 Bone, Electrolyte & Inherited Kidney Disease	
14:30 - 14:50	Interventional Nephrology	KDIGO-KSN Joint Symposium	Recent Update in Renal Pathology	KSN ESRD Registry Report	Clinical Transplantation	Nephrology Board Review Course
14:50 - 15:50				Dialysis Committee		
15:50 - 16:30				Break		
16:30 - 17:00		Major Cohort Studies	Lessons from Major CKD Cohort Studies: Korean & US Cohort	CPC	Chronic Kidney Disease	
17:00 - 17:30						
17:30 - 18:30						

May 21(Sun)						
Room Time	Room 1 Convention Hall 1,2 (4F)	Room 2 Convention Hall 3 (4F)	Room 3 Diamond Hall (3F)	Room 4 Emerald Hall (2) (3F)	Room 5 Emerald Hall (1) (3F)	Grand Ballroom Hotel (2F)
07:30 - 08:30	Registration					
08:30 - 09:30	Dialysis Specialist Physician Course 1	Dialysis Nurse Course 1	Oral Presentation 16 Acute Kidney Injury	Oral Presentation 17 Chronic Kidney Disease	Oral Presentation 18 Diabetes & Obesity	Hands-On-Session
09:30 - 10:30			Oral Presentation 19 Glomerular & Tubulointerstitial Disease	Oral Presentation 20 Chronic Kidney Disease	Oral Presentation 21 Transplantation	
10:30 - 11:00	Coffee Break					
11:00 - 12:30	Dialysis Specialist Physician Course 2	Dialysis Nurse Course 2	Sarcopenia & Frailty in CKD Patients	Glomerular & Tubulointerstitial Disease		Hands-On-Session
12:30 - 13:00						

13:20 - 13:30 **Opening Ceremony** Room 1

Yong-Soo Kim President, The Korean Society of Nephrology
Yong-Lim Kim Congress President, The Korean Society of Nephrology

13:30 - 14:20 **Plenary Lecture I** Room 1

[Chair] **Kyo Sun Kim** Konkuk University, Korea
Yong-Lim Kim Kyungpook National University, Korea

Regulation of epithelial anion transport Min Goo Lee
Yonsei University, Korea

14:30 - 16:30 **Nephrology Education** Korean / Room 1

[Chair] **Nam Ho Kim** Chonnam National University, Korea
Eun Young Lee Soonchunhyang University, Korea

Acid-base/electrolyte imbalance Soo Wan Kim
Chonnam National University, Korea

Urine concentration and key transporters of renal tubules Tae-Hwan Kwon
Kyungpook National University, Korea

Hemodialysis: principle and prescription Dong-Ryeol Ryu
Ewha Womans University, Korea

Peritoneal dialysis: principle and prescription Kook-Hwan Oh
Seoul National University, Korea

14:30 - 16:30 **Basic Renal Pathology** Korean / Room 2

[Chair] **Hyeon Joo Jeong** Yonsei University, Korea
Dong-Wan Chae Seoul National University, Korea

Basic renal pathology: pattern-based approach Beom Jin Lim
Yonsei University, Korea

Practical approach of glomerular disease Ahrim Moon
Soonchunhyang University, Korea

14:30 - 16:30 **Acute Kidney Injury** Room 3

[Chair] **Wonyong Cho** Korea University, Korea
Dong-Jin Oh Seonam University, Korea

Regulated cell death in acute kidney injury Gyu-Tae Shin
Ajou University, Korea

Role of purinergic system in renal ischemia-reperfusion injury Jaeseok Yang
Seoul National University, Korea

Promoting research translation in AKI (and CKD) Robert A. Star
National Institutes of Health, USA

Mechanism of AKI to CKD transition Motoko Yanagita
Kyoto University, Japan

14:30 - 16:30 **Geriatric Nephrology** Room 4

[Chair] **Sang-Youb Han** Inje University, Korea
Jin Joo Cha Korea University, Korea

Current issue of geriatric patients Hidenori Arai
National Center for Geriatrics and Gerontology, Japan

Optimal pharmaceutical therapy for geriatric patients Chang Oh Kim
Yonsei University, Korea

Characteristics of geriatric patients with CKD Ho Jun Chin
Seoul National University, Korea

Frailty, acute kidney injury and mortality in elderly patients Sejoong Kim
Seoul National University, Korea

14:30 - 16:30 **Hypertension & Vascular Biology** Korean / Room 5

[Chair] **Moon-Jae Kim** Inha University, Korea
Eun Hui Bae Chonnam National University, Korea

Altered vascular nitric oxide system in hypertension JongUn Lee
Chonnam National University

Posttranslational modification of mineralocorticoid receptor as a therapeutic target in hypertension InKyeom Kim
Kyungpook National University, Korea

Lymphangiogenesis kidney diseases and hypertension Won Kim
Chonbuk National University, Korea

Functional role of circulating APE1/Ref-1 in vascular inflammation Byeong Hwa Jeon
Chungnam National University, Korea

16:30 - 18:30 **Nephrology Education** Korean / Room 1

[Chair] **Sung Kwang Park** Chonbuk National University, Korea
Hyunjin Noh Soonchunhyang University, Korea

Transplant immunology Chul-Woo Yang
The Catholic University of Korea, Korea

Surgical process of renal transplantation Sun-Cheol Park
The Catholic University of Korea, Korea

Renal transplant pathology Hyeon Joo Jeong
Yonsei University, Korea

Ongoing clinical trials and potential new drugs Sung Gyun Kim
Hallym University Sacred Heart Hospital, Korea

16:30 - 18:30 **Hemodiafiltration** **Korean / Room 2**

[Chair] Young-Il Jo Konkuk University, Korea
Seok Joon Shin The Catholic University of Korea, Korea

Interesting cases of showing the clinical benefits of HDF Yong Kyu Lee
NHIS Ilsan Hospital, Korea

OL-HDF in Korea: current status and challenge Dong-Chan Jin
The Catholic University of Korea, Korea

OL-HDF machine and membrane currently available in Korea Chang Hwa Lee
Hanyang University, Korea

How to prescribe OL-HDF Nam Ho Kim
Chonnam National University, Korea

16:30 - 18:30 **Glomerular & Tubulointerstitial Disease** **Room 3**

[Chair] Kang Wook Lee Chungnam National University, Korea
Kyung Hwan Jeong Kyung Hee University, Korea

Emerging therapeutic challenges in glomerular disease Dae Eun Choi
Chungnam National University, Korea

Renal manifestation in monoclonal gammopathy renal significance (MGRS) Jung Eun Lee
Samsung Medical Center, Korea

Mucosal immune dysregulation and galactose-deficient IgA1 production in IgA nephropathy Yusuke Suzuki
Juntendo University, Japan

Novel biomarkers of obstructive uropathy Rikke Nørregaard
Aarhus University Hospital, Denmark

16:30 - 18:30 **Fluid, Electrolyte & Acid-Base Disorder** **Room 4**

[Chair] Gheun-Ho Kim Hanyang University, Korea
Won Kim Chonbuk National University, Korea

Electrolytes and beyond: new meanings of sodium and potassium as biomarkers Sejoong Kim
Seoul National University, Korea

Pendrin: from bench to bedside Susan M. Wall
Emory University, USA

Claudins and paracellular transport in the proximal renal tubule Alan S. L. Yu
University of Kansas, USA

16:30 - 18:30 **Diabetes & Obesity** **Room 5**

[Chair] Chun Gyoo Ihm Kyung Hee University, Korea
Cheol Whee Park The Catholic University of Korea, Korea

AMPK in diabetic kidney disease Eun Sil Koh
The Catholic University of Korea, Korea

Src tyrosine kinase in diabetic kidney disease Hoon Young Choi
Yonsei University, Korea

New insights into the role of mitochondrial dysfunction in diabetic nephropathy Farhad R. Danesh
The University of Texas, USA

Obesity and kidney disease? Jwa-Kyung Kim
Hallym University Sacred Heart Hospital, Korea

19:00 - 21:00 **Welcome Reception** **Grand Ballroom 2F**

08:30 - 09:20 **Plenary Lecture II** Room 1

[Chair] **Il-Soo Ha** Seoul National University Children's Hospital, Korea
Kee Hwan Yoo Korea University, Korea

Next generation sequencing: revisiting the spectrum of focal segmental glomerulosclerosis and podocyte biology

Corinne Antignac
Laboratory of Hereditary Kidney Diseases Imagine Institute, France

09:30 - 10:00 **Coffee Break & Poster Visit** Convention Centre 1F

10:00 - 12:00 **Diabetes & Obesity** Room 1

[Chair] **Dong Cheol Han** Soonchunhyang University, Korea
Hunjoo Ha Ewha Womans University, Korea

New NOX inhibition in diabetic kidney disease

Jin Joo Cha
Korea University, Korea

Adenosine receptors: new targets for diabetic kidney disease

Hunjoo Ha
Ewha Womans University, Korea

Beta 2 adrenergic receptor is a novel regulator of pro-inflammatory response in diabetes

Hyunjin Noh
Soonchunhyang University, Korea

AKI on CKD: insights from diabetic models

Zheng Dong
Charlie Norwood VA Medical Center, China

10:00 - 12:00 **Chronic Kidney Disease** Room 2

[Chair] **Chun Soo Lim** Seoul National University, Korea
Dae Eun Choi Chungnam National University, Korea

CKD - a crisis in evolution

David Goldsmith
Guy's and St Thomas' Hospital, UK

Mechanism and modulators of kidney fibrosis after tubular injury

Sang-Ho Lee
Khung Hee University, Korea

The role of HIF stabilizer in renal fibrosis

Masaomi Nangaku
University of Tokyo, Japan

Hypertension in chronic kidney disease; Korean perspectives

Ran-hui Cha
National Medical Center, Korea

10:00 - 12:00 **Inherited Kidney Disease** Room 3

[Chair] **Hae Il Cheong** Seoul National University Children's Hospital, Korea
Hee Gyung Kang Seoul National University Children's Hospital, Korea

Monogenic causes in pediatric patients with nephrolithiasis or nephrocalcinosis

Heon Yung Gee
Yonsei University, Korea

Steroid-resistant nephrotic syndrome due to primary CoQ10 deficiency

Hae Il Cheong
Seoul National University Children's Hospital, Korea

Renal ciliopathies

Corinne Antignac
Laboratory of Hereditary Kidney Diseases Imagine Institute, France

Genetic epidemiology of steroid-resistant nephrotic syndrome in Japanese children

Hiroyasu Tsukaguchi
Kansai Medical University Hospital, Japan

10:00 - 12:00 **Peritoneal Dialysis** Room 4

[Chair] **Jun Young Do** Yeungnam University, Korea
Ki Ryang Na Chungnam National University, Korea

When PD teaches HD how to practice: incremental dialysis and residual kidney function

Connie Rhee
University of California Irvine, USA

Peritoneal dialysis: a global understanding of variation in utilization and outcomes

Jeffrey Perl
University of Toronto, Canada

ER stress as a novel target to prevent peritoneal fibrosis in peritoneal dialysis

Duk-Hee Kang
Ewha Womans University, Korea

The past, current and future of peritoneal dialysis in Korea

Seung Hyeok Han
Yonsei University, Korea

10:00 - 12:00 **Hemodialysis** Korean / Room 5

[Chair] **Ihm Soo Kwak** Pusan National University, Korea
Dong-Chan Jin The Catholic University of Korea, Korea

HD quality assessment by HIRA (Government)

Dong-Chan Jin
The Catholic University of Korea, Korea

Malignancy in HD patients - incidence, screening, management

Young-Ki Lee
Hallym University Sacred Heart Hospital, Korea

Surgical consultation of HD patients: risk & complication prevention

Moo Yong Park
Soonchunhyang University, Korea

Strict glucose control for diabetic hemodialysis patients

Jung Tak Park
Yonsei University, Korea


Management of HD patient with liver cirrhosis and ascites

Hyung Jong Kim
CHA University, Korea

Management of HD patient with heart failure & effusion

Sun-Hee Park
Kyungpook National University, Korea


12:00 - 13:00 Luncheon Symposium

Sponsored by CJ Healthcare  **Room 1**

[Chair] Dae Ryong Cha Korea University, Korea

CKD progression and uremic toxin


Wonsuk An
Dong-A University, Korea

Sponsored by Roche Korea  **Room 2**

[Chair] Duk-Hee Kang Ewha Womans University, Korea

How to improve anemia care for dialysis patients?

Sun-Hee Park
Kyungpook National University, Korea

Sponsored by MSD Korea  **Room 3**

[Chair] Yeong Hoon Kim Inje University, Korea

Use of sitagliptin in the management of patients with type 2 diabetes and renal impairment

Sang-Youb Han
Inje University, Korea

Sponsored by Sanofi-Aventis Korea   **Room 4**


[Chair] Yong-Lim Kim Kyungpook National University, Korea

Dietary recommendations for CKD-MBD patients: is P restriction really effective to prevent vascular calcification?

David Goldsmith
Guy's and St Thomas' Hospital, UK

Diagnosis and treatment of Fabry disease by multidisciplinary approach : from a cardiac perspective

Gee Hee Kim
The Catholic University of Korea, Korea

Sponsored by HANDOK  **Room 5**

[Chair] Dong-Chan Jin The Catholic University of Korea, Korea

aHUS: advances in pathogenesis, diagnosis and treatment

Bhadran Bose
Nepean and Blue Mountains Hospital, Australia

13:00 - 14:00 Coffee Break & Poster Visit Convention Centre 1F

14:00 - 15:00 Oral Presentation

1. Acute Kidney Injury **Room 1**

[Chair] Jong-Woo Yoon Hallym University Sacred Heart Hospital, Korea

2. Chronic Kidney Disease **Room 2**

[Chair] Sang Heon Song Pusan National University, Korea

3. Diabetes & Obesity **Room 3**

[Chair] Tae-Hyun Yoo Yonsei University, Korea

4. Dialysis **Room 4**

[Chair] Yeong Hoon Kim Inje University, Korea

5. Transplantation **Room 5**

[Chair] Jong Soo Lee University of Ulsan, Korea

14:00 - 16:00 Kidney Academy Course **Korean / Grand Ballroom**

[Chair] Seok Joon Shin The Catholic University of Korea, Korea

Management of hyperkalemia in chronic kidney disease Jeonghwan Lee
Hallym University Sacred Heart Hospital, Korea

The role of mutation analysis in the field of nephrology Hayne Park
Armed Forces Capital Hospital, Korea

Improving clinical outcomes with high-efficiency hemodiafiltration from a clinician's perspective Kyung Don Yoo
Dongguk University, Korea

Management of hyperphosphatemia in CKD patients Jin Ho Hwang
Chung-Ang University, Korea

15:00 - 16:00 Poster Visit & Poster Presentation Convention Centre 1F

16:00 - 18:00 Transplantation **Room 1**

[Chair] Chul-Woo Yang The Catholic University of Korea, Korea
Beom Seok Kim Yonsei University, Korea

What's new in the management of chronic antibody mediated rejection? Byung Ha Chung
The Catholic University of Korea, Korea

The infectious complications after kidney transplantation: the nephrologist's perspective Natavudh Townamchai
Chulalongkorn University, Thailand

Nonimmunologic complications in kidney transplantation Hyosang Kim
Asan Medical Center, Korea

Current status and management of post-transplant malignancy in Taiwan Ming-Ju Wu
Taichung Veterans General Hospital, Taiwan

16:00 - 18:00 Hemodialysis Room 2

[Chair] Ki Young Na Seoul National University, Korea
Joon Ho Song Inha University, Korea

Blood pressure targets for hemodialysis patients Andrew Davenport
University College London, UK

Clinical impact of vascular calcification in end-stage renal disease patient Tetsuya Ogawa
Tokyo Women's Medical University, Japan

Prevention of cardiovascular complication of HD patients: water volume control Seoung Woo Lee
Inha University, Korea

Vascular calcification HyeonSeok Hwang
The Catholic University of Korea, Korea

Hyperlipidemia Jongha Park
University of Ulsan, Korea

16:00 - 18:00 Nutrition, Inflammation & Metabolism Room 3

[Chair] Yon Su Kim Seoul National University, Korea
Wonsuk An Dong-A University, Korea

Role of inflammation and the uremic milieu in premature vascular aging Peter Stenvinkel
Karolinska Institute, Sweden

Beneficial effects of calorie restriction and protein dilution Daisuke Koya
Kanazawa Medical University, Japan

Salt restriction and CKD progression Chun Soo Lim
Seoul National University, Korea

16:00 - 18:00 Bone & Mineral Disease Room 4

[Chair] Young Joo Kwon Korea University, Korea
Soo Wan Kim Chonnam National University, Korea

Premature ageing drives vascular calcification in chronic kidney disease Catherine M Shanahan
King's College London, UK

An updates on diagnostic methods of vascular calcification in end stage renal disease Yu Ah Hong
The Catholic University of Korea, Korea

Calciophylaxis and vascular calcification: clinical picture and new data Markus Ketteler
Klinikum Coburg, Germany

The ongoing trials in the management of vascular calcification Gang Jee Ko
Korea University, Korea

16:00 - 18:00 Acute Kidney Injury Korean / Room 5

[Chair] Sang Kyung Jo Korea University, Korea
Jaeseok Yang Seoul National University, Korea

Novel biomarkers of acute kidney injury Dong-Jin Oh
Seonam University, Korea

Septic AKI Dong Won Lee
Pusan National University, Korea

Organ cross talk in AKI Eun Hui Bae
Chonnam National University, Korea

AKI treatment: when should we start CRRT? Dong Ki Kim
Seoul National University, Korea

18:30 - 20:30 Gala Dinner Grand Ballroom 2F

07:00 - 08:30 KSN Board of Regent Korean / Grand Ballroom

08:00 - 08:50 Plenary Lecture III Room 1

[Chair] Dong Cheol Han Soonchunhyang University, Korea Hunjoo Ha Ewha Womans University, Korea	
Precision medicine, pragmatic research, and informatics: complementary approaches to advance kidney health	Robert A. Star National Institute of Diabetes and Digestive and Kidney Diseases, USA

09:00 - 10:00 Oral Presentation

6. Chronic Kidney Disease	Room 1
[Chair] Heungsoo Kim Ajou University, Korea	
7. Glomerular & Tubulointerstitial Disease	Room 2
[Chair] Jin Seok Jeon Soonchunhyang University, Korea	
8. Transplantation	Room 3
[Chair] Seungyeup Han Keimyung University, Korea	
9. Geriatric Nephrology	Room 4
[Chair] Bum Soon Choi The Catholic University of Korea, Korea	
10. Hypertension & Vascular Biology	Room 5
[Chair] Jung Hwan Park Konkuk University, Korea	

10:00 - 11:30 Microbiome Room 1

[Chair] Duk-Hee Kang Ewha Womans University, Korea Kwon Moo Park Kyungpook National University, Korea	
Microbiome and genomic medicine	Hansoo Park Gwangju Institute of Science and Technology, Korea
Microbiota-derived metabolites shape mucosal barrier and immunity	Koji Hase Keio University, Japan
Microbiome in acute kidney injury	Hye Ryoung Jang Sungkyunkwan University, Korea

10:00 - 11:30 Bioinformatics & Systems Biology Room 2

[Chair] Tae-Min Kim The Catholic University of Korea, Korea Sang-Ho Lee Khung Hee University, Korea	
Prioritizing treatment targets by integration of genomic variants and tissue specific gene expression pattern	Sek Won Kong Boston Children's Hospital, USA
Incorporating family disease history in risk prediction models with large-scale genetic data substantially dissolves unexplained variability	Sungho Won Seoul National University, Korea
Whole exome sequencing identifies causative mutations of chronic kidney disease	Heon Yung Gee Yonsei University, Korea

10:00 - 11:30 Transporters and Channels Room 3

[Chair] Tae-Hwan Kwon Kyungpook National University, Korea Ki-Hwan Han Ewha Womans University, Korea	
Ammonia (NH ₃) transport – the textbooks were wrong	David Weiner University of Florida, USA
Descending thin limb of the intermediate loop expresses both aquaporin 1 and urea transporter A2 in the mouse kidney	Wan-Young Kim The Catholic University of Korea, Korea
Roles of renal transporters in health and disease	Hitoshi Endou Kyorin University, Japan

10:00 - 11:30 Regulatory RNA Room 4

[Chair] Hyug Moo Kwon Ulsan National Institute of Science and Technology, Korea Sang Geon Kim Seoul National University, Korea	
Novel pathological role and clinical usage of repetitive non-coding RNAs in pancreatic cancer	Motoyuki Otsuka The University of Tokyo, Japan
Role of non-coding RNAs in cellular injury	Sang Geon Kim Seoul National University, Korea
Comprehensive regulatory miRNAs that govern epigenetic machinery in cancer	Suk Woo Nam The Catholic University of Korea, Korea

10:00 - 11:30 Genomic Editing Room 5

[Chair] Soo Wan Kim Chonnam National University, Korea Jung Tak Park Yonsei University, Korea	
Efficient genome editing using CRISPR-Cas9 and -Cpf1	Hyongbum Kim Yonsei University, Korea
Translational research on vaso-proliferative retinopathy using in vivo genome editing	Jeong Hun Kim Seoul National University, Korea
Development of therapeutic genome editing	Seokjoong Kim ToolGen, Inc., Korea

10:00 - 11:30 Ethics Education: Ethics for Life Sustaining Therapy of Patient in End of Life Korean / Grand Ballroom

[Chair] Jong Soo Lee University of Ulsan, Korea	
Clinical application of the hospice, palliative care, and life-sustaining treatment decision-making act	Sang Eun Park Sam Medical Center, Korea
End of life: role of medical personnel	Younsuck Koh University of Ulsan, Korea
Decision of appropriate initiation and withdrawal from dialysis	Seong-Eun Kim Dong-A University, Korea

11:30 - 12:30 Luncheon Symposium Room 1

Sponsored by FMC Korea



Room 1

[Chair] Yong-Soo Kim The Catholic University of Korea, Korea

Vascular access surveillance with BTM

Young-Ki Lee
Hallym University Sacred Heart Hospital, Korea

Sponsored by Baxter



Room 2

[Chair] Kwon Wook Joo Seoul National University, Korea

HDx therapy, the medium cut-off (MCO) membrane with larger pores and higher selectivity to optimize middle molecule removal

Bernd Krause
Gambro Dialysatoren GmbH, Germany

Sponsored by Kyowa Hakko Kirin Korea



Room 3

[Chair] Chun Soo Lim Seoul National University, Korea

Update of anemia management in CKD

Masaomi Nangaku
University of Tokyo, Japan

Sponsored by Otsuka Pharmaceutical



Room 4

[Chair] Hyeong Cheon Park Yonsei University, Korea

Tolvaptan, a novel therapeutic strategy of ADPKD: from theory into practice

Yoshitaka Isaka
Osaka University, Japan

Sponsored by JW Pharmaceutical



Room 5

[Chair] Wonyong Cho Korea University, Korea

New therapeutic option for the treatment of dyslipidemia and hypertension in CKD patients

Sung Gyun Kim
Hallym University Sacred Heart Hospital, Korea

12:30 - 13:30 General Assembly (Award) Room 1

12:30 - 13:30 Poster Visit & Poster Presentation

Convention Centre 1F

13:30 - 14:30 Oral Presentation

11. Chronic Kidney Disease Room 1

[Chair] Young Ok Kim The Catholic University of Korea, Korea

12. Dialysis Room 2

[Chair] Seong Eun Kim Dong-A University, Korea

13. Transplantation Room 3

[Chair] Chan-Duck Kim Kyungpook National University, Korea

14. Nutrition & Inflammation Room 4

[Chair] Soo Bong Lee Pusan National University, Korea

15. Bone, Electrolyte & Inherited Kidney Disease Room 5

[Chair] Yang Wook Kim Inje University, Korea

14:50 - 18:30 Interventional Nephrology Room 1

[Chair] Yong-Soo Kim The Catholic University of Korea, Korea

Takashi Sato Meiko Kyoritsu Clinic, Japan

Current state of interventional nephrology worldwide: where to go?

Tushar Vachharajani
W. G. (Bill) Hefner VA Medical Center, USA

Vascular access management in Japan: role of nephrologists

Takashi Sato
Meiko Kyoritsu Clinic, Japan

How is arteriovenous fistula longevity best prolonged?

Tushar Vachharajani
W. G. (Bill) Hefner VA Medical Center, USA

Access flow surveillance and vascular access outcome

Nicolai Krivitski
Transonic Systems, Inc., USA

Vascular access surveillance: beyond the K/DOQI guidelines

Sung Gyun Kim
Hallym University Sacred Heart Hospital, Korea

Cardiac function assessment during hemodialysis

Nicolai Krivitski
Transonic Systems, Inc., USA

14:30 - 17:00 **KDIGO-KSN Joint Symposium** Room 2

[Chair] Hyeong Cheon Park Yonsei University, Korea
Seungyeup Han Keimyung University, Korea

CKD-MBD in Korea	Young Joo Kwon Korea University, Korea
KDIGO CKD-MBD guideline update 2017: what is new?	Markus Ketteler Klinikum Coburg, Germany
Optimal target of blood pressure in CKD	Seung Hyeok Han Yonsei University, Korea
Hypertension and the kidney: a perspective in 2017	Matthew R. Weir University of Maryland, USA
Kidney transplantation in Korea	Byung Ha Chung The Catholic University of Korea, Korea
Transplantation: long-term risk assessment and prediction in kidney donors: the new KDIGO guidelines and the new calculators	Dorry Segev Johns Hopkins University, USA

14:30 - 16:30 **Recent Update in Renal Pathology** Room 3

[Chair] Moon Hyang Park Konyang University, Korea
Yong Jin Kim Kyungpook National University, Korea

Lupus nephritis	Anthony Chang The University of Chicago, USA
Podocytes and the local complement regulation	Jun Oh University Medical Center Hamburg-Eppendorf, Germany
Diagnosis of amyloidosis: role of mass spectrometry	Sanjeev Sethi Mayo Clinic, USA
SS-31 on BTBR ob/ob diabetic mouse model	Minseob Eom Yonsei University, Korea

14:30 - 14:50 **KSN ESRD Registry Report** Korean / Room 4

[Chair] Yong-Lim Kim Kyungpook National University, Korea

Current renal replacement therapy in Korea - Insan memorial dialysis registry, 2016	Dong-Chan Jin The Catholic University of Korea, Korea
---	--

14:30 - 16:30 **Clinical Transplantation** Korean / Room 5

[Chair] Jin Min Kong Hanseo Hospital, Korea
Su Kil Park University of Ulsan, Korea

Cancer screening of living donor	Sik Lee Chonbuk National University, Korea
Variability of eGFR and allograft outcome	Beom Seok Kim Yonsei University, Korea
Metabolic acidosis and long-term clinical outcome	Jung Pyo Lee Seoul National University, Korea
Pretransplant management of polycystic kidney disease	Chan-Duck Kim Kyungpook National University, Korea

14:30 - 17:30 **Nephrology Board Review Course Chronic Kidney Disease** Korean / Grand Ballroom

[Chair] Cheol Whee Park The Catholic University of Korea, Korea

Chronic kidney disease-mineral bone disorder update	Chang Seong Kim Chonnam National University, Korea
Cardiovascular risk evaluation and management in chronic kidney disease	Ho Jun Chin Seoul National University, Korea
Nutrition and sarcopenia in chronic kidney disease	Su-Hyun Kim Chung-Ang University, Korea

Break(16:00 - 16:15)

[Chair] Chun Soo Lim Seoul National University, Korea

Update of biomarker in chronic kidney disease	Kyung Hwan Jeong Kyung Hee University, Korea
Blood pressure in chronic kidney disease	Dae Eun Choi Chungnam National University, Korea

14:50 - 15:50 **Dialysis Committee** Korean / Room 4

[Chair] Kwon Wook Joo Seoul National University, Korea

2017 Report for Hemodialysis Center Accreditation	Young-Ki Lee Hallym University Sacred Heart Hospital, Korea
---	--

16:30 - 18:30 **Lessons from Major CKD Cohort Studies: Korean & US Cohort** **Room 3**

[Chair] Curie Ahn *Seoul National University, Korea*
Yong-Lim Kim *Kyungpook National University, Korea*

<i>Research into chronic kidney disease insights and discoveries from The CRIC study</i>	Harold Feldman <i>University of Pennsylvania, USA</i>
<i>Lessons learned from the chronic kidney disease in children study</i>	Susan Furth <i>Children's Hospital of Philadelphia, USA</i>
<i>KNOW-CKD: design and overview to major findings</i>	Kook-Hwan Oh <i>Seoul National University, Korea</i>
<i>Baseline characteristics of study subjects in KNOW-CKD cohort</i>	Tae-Hyun Yoo <i>Yonsei University, Korea</i>
<i>Design and major findings of KNOW-pedCKD</i>	Hee Gyung Kang <i>Seoul National University Children's Hospital, Korea</i>

16:30 - 18:30 **CPC** **Korean / Room 4**

Case 1 _ [Chair] So-Young Jin *Soonchunhyang University, Korea*

<i>Internal Medicine</i>	Hye Ryoung Jang <i>Sungkyunkwan University, Korea</i>
<i>Clinical Discussion</i>	Sang Heon Song <i>Pusan National University, Korea</i>
<i>Pathology</i>	Ghee Young Kwon <i>Sungkyunkwan University, Korea</i>

Case 2 _ [Chair] Kwang-Sun Suh *Chungnam National University, Korea*

<i>Internal Medicine</i>	Jae Yoon Park <i>Dongguk University, Korea</i>
<i>Clinical Discussion</i>	Yang Gyun Kim <i>Kyung Hee University, Korea</i>
<i>Pathology</i>	Gang Min Han <i>Dongguk University, Korea</i>

Case 3 _ [Chair] Yeong-Jin Choi *The Catholic University of Korea, Korea*

<i>Internal Medicine</i>	Hajeong Lee <i>Seoul National University, Korea</i>
<i>Clinical Discussion</i>	Hyosang Kim <i>Asan Medical Center, Korea</i>
<i>Pathology</i>	Kyung Chul Moon <i>Seoul National University, Korea</i>

16:30 - 18:30 **Chronic Kidney Disease** **Korean / Room 5**

[Chair] Sung Bae Park *Keimyung University, Korea*
Dae Joong Kim *Sungkyunkwan University, Korea*

<i>Long-term effect of diet modification for CKD patients</i>	Ho Jun Chin <i>Seoul National University, Korea</i>
<i>Diabetic CKD; pathogenesis & factors of progression</i>	Cheol Whee Park <i>The Catholic University of Korea, Korea</i>
<i>Session- management of secondary hyperparathyroidism</i>	Young Joo Kwon <i>Korea University, Korea</i>
<i>Cardiovascular risk burdens in CKD</i>	Sung Gyun Kim <i>Hallym University Sacred Heart Hospital, Korea</i>

17:00 - 18:30 **Major Cohort Studies** **Room 2**

[Chair] Suk Young Kim *The Catholic University of Korea, Korea*
Seung Hyeok Han *Yonsei University, Korea*

<i>Characteristics of PKD genes among rapid progressors in ADPKD patients: a next-generation sequencing study in Korea</i>	Hyunsuk Kim <i>Hallym University Sacred Heart Hospital, Korea</i>
<i>The association of RAAS blockade and the progression of residual kidney function decline: a nation-wide prospective cohort study</i>	Kyung Don Yoo <i>Dongguk University, Korea</i>
<i>Chronic kidney disease-mineral bone disorder in Korean patients: a report from the Korean cohort study for outcomes in patients with chronic kidney disease (KNOW-CKD)</i>	Chang Seong Kim <i>Chonnam National University, Korea</i>
<i>Impact of acute kidney injury in marginal deceased donors on the clinical outcomes of corresponding kidney transplant recipients</i>	Woo Yeong Park <i>Keimyung University, Korea</i>
<i>Relationship between serum uric acid and mortality in Korean hemodialysis patients: results from end-stage renal disease registry</i>	Chang Seong Kim <i>Chonnam National University, Korea</i>
<i>Renal outcomes in patients with middle east respiratory syndrome-coronavirus in Korea</i>	Jieun Oh <i>Hallym University Sacred Heart Hospital, Korea</i>

08:30 - 10:30 **Dialysis Specialist Physician Course 1** **Korean / Room 1**

[Chair] Seung Hwan Sohn Dr. Sohn's Medical Clinic, Korea

Prevention of arteriovenous fistular nonmaturation : from creation	Young Ok Kim The Catholic University of Korea, Korea
Treatment of complicated access patients: aneurysms, infection, acute/chronic thrombosed and steal syndrome	Do Kyun Kim Dr. Kim's Vascular Surgery, Korea
Relationship between arteriovenous access flow and cardiovascular risk factors in HD patients	Do Hyoung Kim Hallym University Sacred Heart Hospital, Korea

08:30 - 10:30 **Dialysis Nurse Course 1** **Korean / Room 2**

[Chair] Chang Suk Yi Dankook University, Korea
Mi Soon Kim Asan Medical Center, Korea

Water treatment for hemodialysis	Eun Ju Jeong Gangnam Severance Hospital, Korea
Environmental management in dialysis facility	Jin Young Hong Samsung Medical Center, Korea
The effects on interdialytic weight gain, self efficacy and self-care behavior in hemodialysis patient by using mobile application for self management	Kyung Jin Baek Asan Medical Center, Korea

08:30 - 09:30 **Oral Presentation**

16. Acute Kidney Injury	Room 3
[Chair] Kyu-Beck Lee Sungkyunkwan University, Korea	
17. Chronic Kidney Disease	Room 4
[Chair] Yun Kyu Oh Seoul National University, Korea	
18. Diabetes & Obesity	Room 5
[Chair] Jung Pyo Lee Seoul National University, Korea	

08:30 - 11:00 **Hands-On-Session** **Korean / Grand Ballroom**

Basic course on ultrasonographic access surveillance	Sun Ryoung Choi Sahmyook Medical Center, Korea
---	--

09:30 - 10:30 **Oral Presentation**

19. Glomerular & Tubulointerstitial Disease	Room 3
[Chair] Ja-Ryong Koo Hallym University Sacred Heart Hospital, Korea	
20. Chronic Kidney Disease	Room 4
[Chair] Dong-Ryeol Ryu Ewha Womans University, Korea	
21. Transplantation	Room 5
[Chair] Hyosang Kim Asan Medical Center, Korea	

10:30 - 11:00 **Coffee Break** **Room 1 - Room5**

11:00 - 12:30 **Dialysis Specialist Physician Course 2: Dialysis complication** **Korean / Room 1**

[Chair] Seong Nam Kim Dr. Kim's Medical Clinic

Ischemic heart disease in dialysis patients: prevention and management	Hack-Lyoung Kim Seoul National University, Korea
Intradialytic hypertension & hypotension	Jung-ho Shin Chung-Ang University, Korea
Hypoxemia as a novel risk factor for dialysis patients	Soon Hyo Kwon Soonchunhyang University, Korea

11:00 - 13:00 **Dialysis Nurse Course 2** **Korean / Room 2**

[Chair] Dong Ho Yang CHA University, Korea
Young-Ki Lee Hallym University Sacred Heart Hospital, Korea

Cardiovascular problems in dialysis patients: an overview	Ji Eun Lee Wonkwang University, Korea
On-line hemodiafiltration: what's new?	Hyunwook Kim Yonsei University, Korea
Recent guidelines on the management of hemodialysis patients	Jieun Oh Hallym University Sacred Heart Hospital, Korea
New drugs prescribed for dialysis patients	Kum Hyun Han Inje University, Korea

11:00 - 13:00 Sarcopenia & Frailty in CKD Patients Korean / Room 3

[Chair] Duk-Hee Kang Ewha Womans University, Korea
Sung Gyun Kim Hallym University Sacred Heart Hospital, Korea

Overview of sarcopenia and frailty in CKD population	Young Rim Song Hallym University Sacred Heart Hospital, Korea
Rehabilitation program in dialysis patients - experience & update 2017	Jae Young Im Seoul National University, Korea
Practical prescription of exercise for dialysis patients	Jun-Chul Kim CHA University, Korea
Prevention and treatment – update 2017	Seok Hui Kang Yeungnam University, Korea

11:00 - 13:00 Glomerular & Tubulointerstitial Disease Korean / Room 4

[Chair] Jung Woo Noh Hallym University Sacred Heart Hospital
Kyu Bok Choi Ewha Womans University, Korea

SGLT-2 inhibitor in diabetic nephropathy	Eun Young Lee Soonchunhyang University, Korea
Management of autosomal dominant polycystic kidney disease- recent update	Ki Ryang Na Chungnam National University, Korea
Clinical impact of drug induced tubulointerstitial nephritis	Soon Kil Kwon Chungbuk National University, Korea

11:00 - 13:00 Hands-On-Session Korean / Grand Ballroom

Introduction for US-guided intervention	Seong Cho Samsung Changwon Hospital, Korea
---	---

Friday, 19 May (14:00 - 15:00)

Oral Presentation 1 / Acute Kidney Injury Room 1

Presentation No.	Title	Presenting Author
KSN-17-0001	A comparative study on the effectiveness and safety of intravenous or oral N-acetylcysteine plus hydration versus hydration alone in preventing contrast-induced nephropathy in adult patients with renal disease	Karl Paolo Dillera
KSN-17-0003	Oxidative stress caused by activation of NADPH oxidase 4 promotes colistin-induced acute kidney injury	Se-Hee Yoon
KSN-17-0009	PGC-1 α attenuates hydrogen peroxide-induced apoptotic cell death by regulating the p38/GSK3 β /Nrf-2 axis in HK-2 cells	Hoon-In Choi
KSN-17-0005	Acute kidney injury increases gut permeability and provoke dysregulation of mucosal immunity: effect of probiotics on AKI severity	Jihyun Yang
KSN-17-0006	Calcium channel blockers and contrast induced nephropathy: a meta analysis of randomized controlled trials	Michelle Ardales

Oral Presentation 2 / Chronic Kidney Disease Room 2

Presentation No.	Title	Presenting Author
KSN-17-0032	Cardiac complications and genotype-phenotype correlations in patients with autosomal dominant polycystic kidney disease in the Korean cohort study for outcomes in patients with KNOW-CKD cohort: an analysis	Hyunsuk Kim
KSN-17-0023	Stanniocalcin-1 inhibits ER stress and renal fibrosis via an AMP-activated protein kinase-dependent pathway in HK2 cells	Eun Mi Yang
KSN-17-0024	Optimal target for blood pressure control in patients with chronic kidney disease: the results from the KNOW-CKD study	Jong Hyun Jhee
KSN-17-0025	Weight loss has an additive effect on the anti-proteinuric effects of angiotensin II receptor blockers in hypertensive patients with chronic kidney disease	Shin Young Ahn
KSN-17-0026	The association between ambulatory blood pressure patterns and body fluid volume in patients with chronic kidney disease	Youn Kyung Kee

Oral Presentation 3 / Diabetes & Obesity Room 3

Presentation No.	Title	Presenting Author
KSN-17-0008	*KSN Grant (FMC Korea, 2016) The roles of mitochondrial dynamics in the pathogenesis of diabetic nephropathy	So-Young Lee
KSN-17-0045	Differential relationship between body fat distribution and all-cause mortality	Sung Woo Lee
KSN-17-0047	Paclitaxel ameliorates Palmitate-induced podocyte injury	Seung Seob Son
KSN-17-0048	Association between time-updated body mass index and the development of chronic kidney disease: a nationwide cohort study	Seung Hyeok Han
KSN-17-0089	A novel oxidative stress biomarker, APX-501, protein is a promising new biomarker for the initiation and progression of diabetic nephropathy in type 2 diabetic patients	Ho Lee

Oral Presentation List

Oral Presentation 4 / Dialysis Room 4

Presentation No.	Title	Presenting Author
KSN-17-0054	NMR based metabolite analysis of PD fluid for early non-invasive detection of infectious peritonitis	Nitin Bajpai
KSN-17-0055	Outcomes of Korean dialysis patients	Dong-Ryeol Ryu
KSN-17-0056	Association of serum lipid levels over time with survival in incident peritoneal dialysis patients	Cheol Ho Park
KSN-17-0092	Natural killer cell activity: a promising tool to screen for malignancy in hemodialysis patients	Seok-Hyung Kim
KSN-17-0099	Outcome of endovascular salvage of immature hemodialysis arteriovenous fistulae	Yaeni Kim

Oral Presentation 5 / Transplantation Room 5

Presentation No.	Title	Presenting Author
KSN-17-0072	C3D-binding ANTI-DQ is associated with high risk for ABMR and graft failure in stable kidney transplant recipients	Dong Ryeol Lee
KSN-17-0073	Clinical outcomes of patients with BK viremia in ABO-incompatible kidney transplantation compared to ABO-compatible kidney transplantation	Jung A Yoon
KSN-17-0082	Cordyceps sinensis protects against tacrolimus-induced renal and pancreatic injury in rats	Jizhe Jin
KSN-17-0075	Does early conversion to MTOR inhibitors epitomise a decorous choice in renal transplant recipients?	Kumar Jayant
KSN-17-0076	Oxidized adenosine triphosphate, a P2X7 receptor antagonist, ameliorates renal ischemia-reperfusion injury through expansion of regulatory T cells	Tai Yeon Koo

Saturday, 20 May (09:00 - 10:00)

Oral Presentation 6 / Chronic Kidney Disease Room 1

Presentation No.	Title	Presenting Author
KSN-17-0027	The prediction of systolic blood pressure at representative time-points for 24 hour mean systolic blood pressure on 1-year cardiovascular outcomes in chronic kidney disease patients	Jiwon Ryu
KSN-17-0028	Smoking is a risk factor for the progression of chronic kidney disease: from the Korean cohort study for outcome in patients with chronic kidney disease	Sangmi Lee
KSN-17-0029	The effect of statin therapy on clinical outcomes in patients with chronic kidney disease: the results from the KNOW-CKD	Min-Uk Cha
KSN-17-0030	The effects of coffee intake on the incident chronic kidney disease in general population	Jong Hyun Jhee

Oral Presentation List

Oral Presentation 7 / Glomerular & Tubulointerstitial Disease Room 2

Presentation No.	Title	Presenting Author
KSN-17-0085	<i>*KSN Grant (Kyowa Hakko Kirin Korea, 2016)</i> Role of insulin-like growth factor binding protein 3 - sphingosine kinase 1 pathway in renal tubulointerstitial fibrosis	Mi Jung Lee
KSN-17-0058	Expression of CD71 mesangial IgA1 receptor predicts progression of IgA nephropathy	Jong Hyun Jhee
KSN-17-0059	Glomerular glucocorticoid receptor expression associates with treatment response and prognosis in patients with IgA nephropathy	Youn Kyung Kee
KSN-17-0060	The effect of Akt1 on glomerulosclerosis of non obstructed kidney: unilateral ureteral obstruction mice model with Akt1 deletion	Sang Heon Song
KSN-17-0094	Urinary metabolomic study in patients with membranous nephropathy	Hyung Ah Jo

Oral Presentation 8 / Transplantation Room 3

Presentation No.	Title	Presenting Author
KSN-17-0077	Clinical significance of BK virus-specific T cell immunity monitoring using ELISPOT assay in kidney transplant recipients	Ji-Yeun Chang
KSN-17-0078	The clinical relevance of cell-free nuclear and mitochondrial DNA at early postoperative period in kidney transplant recipients	Kipyo Kim
KSN-17-0019	Targeting histone deacetylase in renal tubular epithelial cells inhibits amplification of TH1 cell-mediated inflammation	Sunwoo Kang
KSN-17-0109	Effect of empagliflozin on tacrolimus-induced pancreas is let dysfunction and renal injury	Kang Luo
KSN-17-0102	Long-term outcomes of stratified desensitization therapy based on immunological risk in living donor kidney transplantation	Tae Hyun Ban

Oral Presentation 9 / Geriatric Nephrology Room 4

Presentation No.	Title	Presenting Author
KSN-17-0093	Sirt1-induced hypoxia-inducible factor-1 deacetylation attenuates tubular damage in aged kidney	Hyunjin Noh
KSN-17-0051	Prognostic impact of APACHE II in the prediction of long term patient survival in the elderly acute kidney injury patients who underwent continuous renal replacement therapy	Harin Rhee
KSN-17-0052	Deletion of the gene for adiponectin accelerates age-related kidney injury	Eun Hui Bae
KSN-17-0053	Carotid intimomedial thickness as a primary marker of atherosclerosis in 100 patients of chronic kidney disease aged above 50 years	Mayur Patil
KSN-17-0100	Altered metabolism of blood manganese is associated with low level of hemoglobin in the patients with chronic kidney disease	Minyoung Kim

Oral Presentation List

Oral Presentation List

Oral Presentation 10 / Hypertension & Vascular Biology Room 5

Presentation No.	Title	Presenting Author
KSN-17-O061	The clinicopathologic and prognostic features of microangiopathic hemolytic anemia in the setting of IgA nephropathy with malignant hypertension	Chen Pu
KSN-17-O062	Association of chronic coffee consumption with blood pressure and albuminuria	Se Won Oh
KSN-17-O063	Effects of Empagliflozin on solitary rat kidneys producing doxorubicin-induced nephrotic syndrome	Chor Ho Jo
KSN-17-O064	Association between time-updated systolic blood pressure and the incident chronic kidney disease: a nationwide cohort study	Seung Hyeok Han
KSN-17-O096	Asymptomatic hyperuricemia is independently associated with coronary artery calcification in the absence of overt coronary artery disease: a single-center cross-sectional study	Kwon Soo Jung

Saturday, 20 May (13:30 - 14:30)

Oral Presentation 11 / Chronic Kidney Disease Room 1

Presentation No.	Title	Presenting Author
KSN-17-O022	Proton pump inhibitors use and the risk of chronic kidney disease: evidence based systematic review and meta-analysis	Salman Hussain
KSN-17-O033	Serum fibroblast growth factor-23 levels are associated with an increased risk of developing anemia in patients with non-dialysis chronic kidney disease	Ki Heon Nam
KSN-17-O034	High dietary phosphorus intake is a risk factor for incident chronic kidney disease development in diabetic subjects: a community-based prospective cohort study	Seong Yeong An
KSN-17-O035	The relationship between serum leptin and nutritional status in end stage renal disease without dialysis	Jun Young Lee
KSN-17-O036	Podocyte and proximal tubular cell participate in the ST2 related renal fibrosis	Yong Chul Kim

Oral Presentation 12 / Dialysis Room 2

Presentation No.	Title	Presenting Author
KSN-17-O091	Comparison of different definitions of low muscle mass in prevalent hemodialysis patients and their relation to muscle strength	Donghwan Oh
KSN-17-O057	Itraconazole ameliorates chlorhexidine gluconate-induced peritoneal fibrosis in mice through regulating Hedgehog signaling pathway	Jin Sug Kim
KSN-17-O090	Association of hepcidin with anemia management in incident dialysis patients: is HD and PD different?	Jeong-Hoon Lim
KSN-17-O098	The exchange technique using over the guidewire from tunneled to tunneled hemodialysis catheter can be performed without increasing infection and compromising catheter long term patency	Hoon Suk Park
KSN-17-O097	The exchange technique using previous venotomy site over the guidewire from non-tunneled to tunneled hemodialysis catheter can be performed without compromising catheter long term patency	Hoon Suk Park

Oral Presentation 13 / Transplantation Room 3

Presentation No.	Title	Presenting Author
KSN-17-O103	The change in carotid arterial inflammation in de novo renal transplant recipients as assessed by 18F-FDG PET/CT	Sang Su Choi
KSN-17-O104	Comparison of microvascular inflammation in renal allograft tissue between ABO incompatible and ABO compatible kidney transplantation	Eun Jeong Ko
KSN-17-O105	Change of bone and mineral metabolism in kidney donors after uninephrectomy; prospective observational study	Eun Jeong Ko
KSN-17-O106	Minimal tacrolimus maintenance dosage with conventional use of enteric-coated mycophenolate sodium for stable kidney transplant recipients: a randomized controlled trial.	Sehoon Park

Oral Presentation 14 / Nutrition & Inflammation Room 4

Presentation No.	Title	Presenting Author
KSN-17-O067	Secondhand smoking is a risk factor for incident chronic kidney disease development	Jong Hyun Jhee
KSN-17-O068	A simplified protein-energy wasting scoring system for survival prediction in Korean incident hemodialysis patients	Young Eun Kwon
KSN-17-O069	Combined therapy of omega-3 fatty acid and cholecalciferol modulates molecules associated with cardiac hypertrophy and sarcopenia in 5/6 nephrectomy rats	Hyuck Jae Choi
KSN-17-O070	Combined treatment with omega-3 fatty acid and cholecalciferol increases 1 25 dihydroxy vitamin d level by inhibiting 24 hydroxylase of kidney and liver in 5/6 nephrectomy rat model	Won Suk An
KSN-17-O071	Elevated serum triglyceride to high-density lipoprotein cholesterol ratio is associated with an increased risk of chronic kidney disease development: a nationwide cohort study	Seung Hyeok Han

Oral Presentation 15 / Bone, Electrolyte & Inherited Kidney Disease Room 5

Presentation No.	Title	Presenting Author
KSN-17-O083	<i>*KSN Grant (KSN Young Investigator Grant, 2016)</i> Soluble RAGE as a potential therapeutic agent in inflammation associated renal injury	Tae-Hyun Yoo
KSN-17-O021	Implementation of Korean CKD-MBD management recommendations in hemodialysis patients: a quality improvement study	Kyubok Jin
KSN-17-O050	Excessive fluid balance increases mortality risk in patients undergoing extracorporeal membrane oxygenation treatment	Hyoungnae Kim
KSN-17-O065	Prevalence of monogenic causes in children with steroid-resistant nephrotic syndrome	Eujin Park
KSN-17-O066	Genetic analysis in patients with congenital anomalies of the kidney and urinary tract	Yo Han Ahn

Saturday, 20 May (17:00 - 18:30)

Major Cohort Studies		Room 2
Presentation No.	Title	Presenting Author
KSN-17-C001	Chronic kidney disease-mineral bone disorder in Korean patients: a report from the Korean cohort Study for outcomes in patients with chronic kidney disease (KNOW-CKD)	Chang Seong Kim
KSN-17-C002	Relationship between serum uric acid and mortality in Korean hemodialysis patients: results from end-stage renal disease registry	Chang Seong Kim
KSN-17-C003	The association of RAAS blockade and the progression of residual kidney function decline: a nation-wide prospective cohort study	Kyung Don Yoo
KSN-17-C004	characteristics of PKD genes among rapid progressors in ADPKD patients: a next-generation sequencing study in Korea	Hyunsuk Kim
KSN-17-C005	Impact of acute kidney injury in marginal deceased donors on the clinical outcomes of corresponding kidney transplant recipients	Woo Yeong Park
KSN-17-C007	Renal outcomes in patients with middle east respiratory syndrome-coronavirus in korea	Jieun Oh

Sunday, 21 May (08:30 - 09:30)

Oral Presentation 16 / Acute Kidney Injury		Room 3
Presentation No.	Title	Presenting Author
KSN-17-O002	<i>*KSN Grant (KSN Young Investigator Grant, 2016)</i> Cilastatin attenuates vancomycin-induced nephrotoxicity via P-glycoprotein	Hyo-Wook Gil
KSN-17-O084	Mitochondrial NADP+-dependent isocitrate dehydrogenase (IDH2) for the treatment of cisplatin-induced nephrotoxicity	Min Jung Kong
KSN-17-O010	PGC-1α protects TGF-β induced fibrosis by suppressing TGFβRI expression affected to Smad2/3 activation	Hoon-In Choi
KSN-17-O011	Effects of anti-fibrotic by RON receptor tyrosine kinase suppression	Jung Sun Park
KSN-17-O004	Diabetes aggravate post-ischemic renal fibrosis through persistent activation of shh signaling	Dongjin Kim

Oral Presentation 17 / Chronic Kidney Disease		Room 4
Presentation No.	Title	Presenting Author
KSN-17-O037	Association between serum HDL cholesterol levels and the progression of chronic kidney disease: the results from the KNOW-CKD	Seung Hyeok Han
KSN-17-O038	The association between cardiac troponin T and left ventricular structure in chronic kidney disease: result from the Korean cohort study for outcomes in patients with chronic kidney disease (KNOW-CKD)	Eunjeong Kang
KSN-17-O039	The association between cardiac troponin t and coronary artery calcification in chronic kidney disease: result from the Korean cohort study for outcomes in patients with chronic kidney disease (KNOW-C)	Eunjeong Kang
KSN-17-O040	Metabolic acidosis is inversely associated with pulse wave velocity in chronic kidney disease: Results from the KNOW-CKD study	Hyo Jin Kim
KSN-17-O041	The association of metabolic acidosis with renal progression in chronic kidney disease: Results from the KNOW-CKD Study	Hyo Jin Kim

Oral Presentation 18 / Diabetes & Obesity		Room 5
Presentation No.	Title	Presenting Author
KSN-17-O012	<i>*KSN Grant (FMC Korea, 2015)</i> Puromycin aminonucleoside induces podocyte apoptosis by endoplasmic reticulum stress	Tae-Sun Ha
KSN-17-O088	AdipoRon ameliorates diabetic nephropathy through activation of intracellular Ca++-AMPKα-PPARα in podocytes and type 2 db/db mice	Yaeni Kim
KSN-17-O014	The impact of sirtuin 3 in renal tubular cell apoptosis under diabetic conditions	Jimin Park
KSN-17-O015	Ferroptosis is involved in renal tubular cell death in diabetic nephropathy	Seonghun Kim
KSN-17-O049	Improved lipotoxicity by fenofibrate ameliorates diabetic nephropathy by attenuating lymphatic proliferation in db/db mice	Yaeni Kim

Sunday, 21 May (09:30 - 10:30)

Oral Presentation 19 / Glomerular & Tubulointerstitial Disease		Room 3
Presentation No.	Title	Presenting Author
KSN-17-O095	<i>*KSN Grant (Kyowa Hakko Kirin Korea, 2015)</i> Tonsillar and fecal microbiome in IgA nephropathy	Ji In Park
KSN-17-O079	Determination of IL-1B (rs16944) and IL-6 (rs1800796) genetic polymorphisms in IgA nephropathy in a northwest Chinese Han population	Jiali Wei
KSN-17-O007	Sulfatide-selective NKT cells mediate M2 to M1 polarization resulting in amelioration of kidney fibrosis.	Sunhwa Lee
KSN-17-O013	Autophagy in FOXD1 stroma-derived cells plays a critical role in renal tubulointerstitial fibrosis	Sun Ah Nam
KSN-17-O017	Kruppel like factor 15 is a crucial suppressor of the glomerular epithelial cell fibrosis in hypertension	Mi-Yeon Yu

Oral Presentation 20 / Chronic Kidney Disease		Room 4
Presentation No.	Title	Presenting Author
KSN-17-O042	Increased plasma ngal levels are independently associated with left ventricular hypertrophy and diastolic dysfunction in patients with chronic kidney disease	Il Young Kim
KSN-17-O043	Genome-wide association studies identify genetic loci related to incident chronic kidney disease	Miyeun Han
KSN-17-O044	Self-reported habitual snoring is associated with incident chronic kidney disease development: a community-based prospective cohort study	Changhyun Lee
KSN-17-O086	The ablation of C/EBP homologous protein (CHOP) attenuates UUO-induced renal fibrosis	Mi Ra Noh
KSN-17-O087	Estimated glomerular filtration during gestation predicts maternal and fetal complications	Sehoon Park

Oral Presentation 21 / Transplantation		Room 5
Presentation No.	Title	Presenting Author
KSN-17-O108	Comparison of the clinical outcomes between living donor and deceased donor kidney transplantation in old aged recipients ; Nationwide cohort study	Eun Jeong Ko
KSN-17-O101	The role of TNFSF13 level and Galactose deficient IgA in recurrent IgA nephropathy after kidney transplantation	Hyung Ah Jo
KSN-17-O080	Renoprotective role of fenoldopam pretreatment on microcirculation after kidney transplantation through heme oxygenase-1 expressions	Yiqiao Li
KSN-17-O081	Attenuation of interstitial inflammation and fibrosis by SHEN-KANG injection in tacrolimus induced kidney injury	Huiying Li
KSN-17-O074	Ginseng extract protects against tacrolimus-induced pancreatic beta cell injury by regulating autophagy	Sun Woo Lim

Acute Kidney Injury		
Presentation No.	Title	Presenting Author
KSN-17-P001	The impact of disease severity on paradoxical association between body mass index and mortality in patients with acute kidney injury undergoing continuous renal replacement therapy	Hyoungnae Kim
KSN-17-P002	Impact of early initiation of continuous renal replacement therapy in critically ill patients with acute kidney injury	Sungyoon Lim
KSN-17-P003	The role of oxidative stress in contrast-induced acute kidney injury	Chandrashekar Annamalai
KSN-17-P004	Acute kidney injury in pediatric cancer patients: incidence and outcome	Peong Gang Park
KSN-17-P005	Study on biological markers of acute kidney injury	Hee Sun Baek
KSN-17-P006	Impact of the colostomy formation on acute kidney injury occurrence in patients undergoing colorectal surgery	Youn Kyung Kee
KSN-17-P007	Long term outcome for patients with acute kidney injury treated with continuous renal replacement therapy: single center experience	Harin Rhee
KSN-17-P008	The clinical implication of computed tomography in predicting severity of acute pyelonephritis associated acute kidney injury	Hyunju Yoon
KSN-17-P009	phosphate is a novel biomarker of disease severity and predicts adverse outcomes in AKI patients undergoing continuous renal replacement therapy	Jaeyeol Kwon
KSN-17-P010	Acute kidney injury, its risk factors, and mortality in chronic obstructive pulmonary disease patients	Eunjin Bae
KSN-17-P011	Preoperative low urine pH predicts acute kidney injury after cardiac surgery	Min-Uk Cha
KSN-17-P012	Clinical characteristics of sepsis patients who were treated with continuous renal replacement therapy	A young Cho
KSN-17-P013	A risk scoring model to predict progression of renal dysfunction in patients with chronic kidney disease complicated with contrast-induced nephropathy	Seung Don Baek
KSN-17-P014	Predictive factors of renal outcome in heart failure patients after heart transplantation	Hee Jin Kwon
KSN-17-P015	Risk factors for mortality in patients with acute kidney injury treated with continuous renal replacement therapy	Yoo Jin Lee
KSN-17-P016	The effect of a hourly urine output on the clinical outcomes in nontraumatic exercise-induced rhabdomyolysis	Won-Jae Shin
KSN-17-P017	Risk factors of development of acute kidney injury in orthopedic surgery	Hae-Won Lee
KSN-17-P018	Clinical outcome and risk factors associated with colistin-induced acute kidney injury	Sangmok Yeo

Presentation No.	Title	Presenting Author
KSN-17-P019	Acute kidney injury in the patients with alcoholic ketoacidosis and delta neutrophil index as a prognostic factor	Jae Won Yang
KSN-17-P020	Collecting duct cell specific mitochondrial dysfunction influence to inflammation and fibrosis in UUO mice	Jin Young Jeong
KSN-17-P021	TGF-β1 induces Nox4 dependent hypoxia induced apoptosis in human kidney proximal tubular epithelial cells	Sungkwon Cho
KSN-17-P022	Omega 3 attenuates contrast induced nephropathy	Jin Young Jeong
KSN-17-P023	Necro X7 attenuates contrast induced nephropathy	Jin Young Jeong
KSN-17-P024	Screenshot for CRRT management	Anna Lee
KSN-17-P025	Paricalcitol ameliorates radiocontrast-induced nephropathy	Tae Won Lee
KSN-17-P026	Hypochloremia or hyperchloremia: which one is more associated with the development of contrast-induced nephropathy?	Hyung Jung Oh
KSN-17-P027	Clinical aspects of IgG4-related retroperitoneal fibrosis in single center study	Yoon kyung Choi
KSN-17-P028	Can urinary [TIMP2]/[IGFBP-7] predict acute kidney injury after femur neck fracture reduction operation?(pilot study)	Woori Cho
KSN-17-P029	Mitochondrial DNA augments the inflammatory response in acute kidney injury	Haena Moon
KSN-17-P030	A case of acute kidney injury after carbon monoxide poisoning	Young Min Yoon
KSN-17-P031	Timing for initiation of sequential continuous renal replacement therapy in patients with extracorporeal membrane oxygenation: a propensity score analysis	Jin Hyuk Paek
KSN-17-P032	Impact of early initiation of continuous renal replacement therapy in critically ill patients with acute kidney injury	Sung Yoon Lim
KSN-17-P033	Urine TIMP-2 and IGFBP7 can predict adverse renal outcome in established acute	Sung Yoon Lim
KSN-17-P034	Beneficial effect of α-mangostin on acute kidney injury in rats via PI3K/Akt/Nrf2 signaling pathway	Vikas Kumar
KSN-17-P173	Febuxostat in the reduction of serum uric acid in patients at risk of tumor lysis syndrome: a systematic review	Maia Gajo
KSN-17-P174	Studies on renal protective role of debelolactone in renal reperfusion/ischemia induced acute kidney injury via PI3K/Akt/Nrf2 signalling pathways	Amita Verma

Presentation No.	Title	Presenting Author
KSN-17-P192	Bile acid cast nephropathy associated with acute hepatitis A	Jong Hwan Jung
KSN-17-P193	A case of Lesch-Nyhan syndrome in an adult presented with acute kidney injury	A Young Cho
KSN-17-P194	Ticagrelor-induced acute kidney injury can increase serum concentration of statin, and lead to concurrence of rhabdomyolysis	Inseong Park
KSN-17-P195	Epidemiologic survey of spinning induced rhabdomyolysis	Jong Cheol Jeong
KSN-17-P196	The influence of hypophosphatemia on outcomes during CRRT in AKI patients	Hyo Jong Kim
KSN-17-P197	Two cases of complications associated with carbon monoxide poisoning: acute kidney injury, rhabdomyolysis and delayed leukoencephalopathy	Gun Woo Kang
KSN-17-P198	Rhabdomyolysis associated with fenofibrate leading to respiratory failure in a patient with diabetic chronic kidney disease	Tae Won Lee
KSN-17-P199	Acute kidney injury and rhabdomyolysis after carbon monoxide poisoning in patient with hepatitis B	Heeryong Lee
KSN-17-P200	Synergistic effects of acute kidney injury and chronic kidney disease on the development of end-stage renal disease after coronary artery bypass grafting	Yeonhee Lee
KSN-17-P201	Utility of volume assessment using bioelectrical impedance analysis in critically ill patients receiving continuous renal replacement therapy: a prospective observational study	So-Hee Jeong
KSN-17-P202	Heart rate is associated with mortality in continuous renal replacement therapy	Soojin Lee
KSN-17-P203	Complex relationship among obesity, acute kidney injury, and long-term mortality in coronary artery bypass grafting	Hongran Moon
KSN-17-P204	Long-term clinical impacts of cumulative fluid balance in continuous renal replacement therapy	Jung Nam An
KSN-17-P205	Association of clinical factors and the outcome of patients on continuous renal replacement therapy in intensive care units	Ha Nee Jang
KSN-17-P206	Methionine sulfoxide reductase B3 (MsrB3)-gene deletion exacerbates vitaminD3-induced kidney injury	Hong Seok Choi
KSN-17-P207	Acute kidney injury in cancer patients: risk factors and impact on mortality	Eunjeong Kang
KSN-17-P208	Clinical, biochemical and physical parameters associated with severe acute kidney injury in patients with hantaan virus infections: results from a single-center prospective cohort study	Hayne Park
KSN-17-P209	Low serum bicarbonate levels at admission predict the development of hospital acquired acute kidney injury: a retrospective cohort study	Sung Yoon Lim

Basic Science (Cell Biology)		
Presentation No.	Title	Presenting Author
KSN-17-P035	The effect of SIRT3 on CsA induced renal cell apoptosis	Jieun Kim
KSN-17-P036	Uremic solutes of indoxyl sulfate and p-cresol enhance protease activated receptor-2 expression in human skin and a chronic kidney disease mouse model	Sung Jin Moon
KSN-17-P037	Differentiation to kidney precursor cells from mouse embryonic stem cells	Tung Nguyen-Thanh
KSN-17-P038	Activated farnesoid X receptor by GW4064 protects against renal fibrosis in HK2 cells	Dong-hyun Kim
KSN-17-P039	APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice	Jung-Hwa Ryu
KSN-17-P040	Protective effects of green tea extract and gemigliptin on acute tacrolimus-induced nephropathy in mice	ByungChul Shin
KSN-17-P175	Tripterygium glycoside up-regulates autophagy to protect the podocyte injury induced by puromycin aminonucleoside	Jianguang Gong
KSN-17-P210	HDAC1 inhibition by valproic acid attenuates TGF- β -induced renal fibroblast activation and extracellular matrix protein production in mouse UUO model	Tùng Nguyễn Thanh
KSN-17-P211	Podocyte exosomal MicroRNA profiling by next generation sequencing	Soon Hyo Kwon
KSN-17-P212	The effect of APX-115 on chronic renal injury in an experimental murine model of unilateral ureteral obstruction	Jin Joo Cha
KSN-17-P213	Rg3 inhibits puromycin induced apoptosis in human podocyte through suppression of ER stress	Haekyung Lee
KSN-17-P214	The effects of periostin on the aging process	Jung Nam An
KSN-17-P215	Cyclosporine, but not tacrolimus, intracellular concentration is affected by simvastatin through MRP1 inhibition in Jurkat cells	Seok Ju Park
KSN-17-P308	The NRF2-heme oxygenase-1 system modulates autophagy and inhibits high glucose induced apoptosis in renal tubular epithelial cells	Young Woong Song
KSN-17-P309	ER stress and polyuria in α -galactosidase deficient mice	Ki-Hwan Han

Bone and Mineral Disease		
Presentation No.	Title	Presenting Author
KSN-17-P216	Case report: Primary hyperparathyroidism caused by parathyroid carcinoma resulting in renal insufficiency	Wonjung Choi
KSN-17-P217	A rare case report : Erdheim chester disease(ECD) and langerhans cell histiocytosis(LCH) overlap syndrome presenting as Brown tumor in a patient with CKD-hemodialysis	HonJin Bae
KSN-17-P310	Combination of omega-3 fatty acid and menaquinone-7 prevents progression of aortic calcification in adenine and low protein diet induced rat model	Young Ki Son

Chronic Kidney Disease (Non-Dialysis)		
Presentation No.	Title	Presenting Author
KSN-17-P041	The duration of female reproductive period is associated with incident chronic kidney disease: a community-based prospective cohort study	Shinchan Kang
KSN-17-P042	Association between OH/ECW and echocardiographic parameters of CKD patients not undergoing dialysis	Jin Sae Yoo
KSN-17-P043	Serum hepcidin may be a uremic toxin: results from the Korean cohort study for outcomes in patients with chronic kidney disease (KNOW-CKD)	Se-jin Lee
KSN-17-P044	Hepcidin is associated with Left ventricular hypertrophy in patient with non-dialysis chronic kidney disease	Hyang Ki Min
KSN-17-P045	High serum adiponectin is associated with anemia development in chronic kidney disease: The results from the KNOW-CKD study	Hyoungnae Kim
KSN-17-P046	GLP-1 receptor activation by DPP-4 inhibitor in chronic kidney disease rat with myocardial infarction	Soon Kil Kwon
KSN-17-P047	Circulating osteoglycin predicts all-cause mortality and major cardiovascular events in patients with advanced chronic kidney disease: a retrospective analysis of a randomized controlled study	Seon Ha Baek
KSN-17-P048	Circulating reninase predicts all-cause mortality and renal outcome in patients with advanced chronic kidney disease	Seon Ha Baek
KSN-17-P049	Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells	Soon Youn Choi

Presentation No.	Title	Presenting Author
KSN-17-P050	Fibroblast growth factor-23 is not a better marker of cardiovascular risk than phosphate in patients with chronic kidney disease	Misol Lee
KSN-17-P051	The impact of albuminuria on serum phosphate level via modulating tubular reabsorption in chronic kidney disease: result from the KNOW-CKD study	Hyoungnae Kim
KSN-17-P052	Low serum intact parathyroid hormone has increased risk of coronary arterial calcification in chronic kidney disease patients: result from the KNOW-CKD study	Hyoungnae Kim
KSN-17-P053	High sensitivity C-reactive protein associates with an increased risk for cardiovascular disease and all-cause death, but not with progression of chronic kidney disease: the results from the KNOW-CKD	Youn Kyung Kee
KSN-17-P054	CKD-EPI equation is better than MDRD equation in predicting coronary artery calcification in CKD patients: from the KNOW-CKD study	Young Youl Hyun
KSN-17-P055	Differential role of fluid overload versus arterial stiffness on the development of high blood pressure in patients at risk of cardiovascular disease	Seohyun Park
KSN-17-P056	The association between alcohol consumption and renal outcome is modified by chronic kidney disease stages	Heebyung Koh
KSN-17-P057	Concomitant acute pyelonephritis affects renal outcome in obstructive uropathy by urolithiasis	Jin Ho Hwang
KSN-17-P058	Clinical profile and outcome of children with chronic kidney disease from a socio-economically disadvantaged population	Richa Prakash Patil
KSN-17-P059	Urine osmolality and renal outcome in patients with chronic kidney disease: the results from the KNOW-CKD	Mi Jung Lee
KSN-17-P060	The factors influenced on change in systolic blood pressure variability in Chronic kidney disease patients: the APrODiTe-2 1-year follow-up study	Jiwon Ryu
KSN-17-P061	The effect of febuxostat on the preservation of glomerular filtration rate in non-diabetic patients with CKD	Inseong Park
KSN-17-P062	Prognostic relationships between small vessel disease and renal dysfunction in acute ischemic stroke survivors	Jae Woong Jeon
KSN-17-P063	Omega 3 fatty acid ameliorates renal fibrosis in UUO mice via enhancement of autophagy flux	Yoon-Kyung Chang

Presentation No.	Title	Presenting Author
KSN-17-P064	Inhibition of KLHL3 ameliorates renal fibrosis in UUO mice	Yoon-Kyung Chang
KSN-17-P065	Serum uric acid showed significant association with coronary artery calcification in only early chronic kidney disease: results from the Korean cohort study for outcomes in patients with chronic kidney	Miyeun Han
KSN-17-P066	Vascular calcification and left ventricular hypertrophy in hemodialysis patients: interrelationship and clinical impacts	Hyeon Seok Hwang
KSN-17-P067	Neutrophil to lymphocyte ratio is an independent predictor of severity of coronary artery disease in patients with chronic kidney disease	Il young Kim
KSN-17-P068	Left-ventricular hypertrophy and diastolic dysfunction in children with chronic kidney disease	Yeonhee Lee
KSN-17-P069	Sirtuin 1 as a biomarker for cardiovascular and mineral bone disease in hemodialysis patients	Su Woong Jung
KSN-17-P177	Autophagy activity and expression pattern of autophagy-related markers in the podocytes of patients with lupus nephritis: association with pathological classification	Juan Jin
KSN-17-P178	The novel involvement of podocyte autophagic activity in the pathogenesis of lupus nephritis	Juan Jin
KSN-17-P218	A case report of pseudoaneurysm of the esophageal artery and Takayasu arteritis in an autosomal dominant polycystic kidney disease patient	Yeonsil Yu
KSN-17-P219	Retinopathy and left ventricular hypertrophy in patients with chronic kidney disease: interrelationship and impact on clinical outcomes	Yaeni Kim
KSN-17-P220	Renoprotective effect of dipeptidyl peptidase-4 inhibitor in aging mice	Tae Hyun Ban
KSN-17-P221	Low urinary potassium excretion is associated with progression of chronic kidney disease: the results from the KNOW-CKD	Hyung Woo Kim
KSN-17-P222	Occurrence and risk factors of kidney outcome among patients with rheumatoid arthritis	Minah Kim
KSN-17-P223	Chronic kidney disease(CKD) patients are exposed to more proton pump inhibitor(PPI)s compared to non-CKD patients; in a single center out-patient clinic	Lee Hee Jeong

Presentation No.	Title	Presenting Author
KSN-17-P224	Peripheral pulse wave velocity (PWV) may be more predictive of rapid decline of kidney function than central PWV in KNOW-CKD Cohort	Sung Woo Lee
KSN-17-P225	Relationship between kidney function and liver fibrosis in subjects with biopsy-proven nonalcoholic fatty liver disease	Jeonghwan Lee
KSN-17-P226	The effects of pazopanib versus sunitinib on renal outcome in metastatic renal cell carcinoma	Eun Jeong Lee
KSN-17-P227	Development of an equation to estimate the glomerular filtration rate in Korean children with chronic kidney diseases	Hyun Jin Choi
KSN-17-P228	Assessment of volume status in edematous chronic kidney disease patients; what to choose	Hye Sook Min
KSN-17-P229	Association of apolipoprotein A1 and B with coronary calcification and chronic kidney disease in the big data	Seok-Hyung Kim
KSN-17-P230	The association of serum total bilirubin with renal progression in chronic kidney disease: results from the KNOW-CKD Study	Hyo Jin Kim
KSN-17-P231	Relationships of dietary phosphate intake and serum phosphate with clinical outcomes in chronic kidney disease patients: findings from the Korean cohort study for outcome in patients with chronic kidney	Hong Sang Choi
KSN-17-P232	Association between chronic kidney disease and muscle strength in Korean population	A Young Kim
KSN-17-P233	The clinical significances of disability in maintenance dialysis patients	Seok Hui Kang
KSN-17-P234	Association between periodontitis and low-grade albuminuria in non-diabetic adults	Kei Lim Shin
KSN-17-P235	The association between chronic kidney disease and obese population with or without metabolic disturbances: a population based study	Soon Seon Im
KSN-17-P307	Cerebrovascular phenotype and genotype correlation in ADPKD patients: using next-generation sequencing study in Korea	Hyunsuk Kim
KSN-17-P313	The baseline characteristics of the ADPKD sub-cohort in the Korean cohort study for outcomes in patients with chronic kidney disease (KNOW-CKD)	Junga Koh

Diabetes and Obesity		
Presentation No.	Title	Presenting Author
KSN-17-P070	Multifunctional Nano constructs for paroral delivery of Insulin	Saurabh Bhargava
KSN-17-P071	A Spatial Distribution of Two Isoforms of Matrix Metalloproteinase-2 In Murine Diabetic Kidney according to the Time of Diabetic Milieu	Sang Heon song
KSN-17-P072	Effect of bariatric surgery on renal function in Asian cohort	Pei loo Tok
KSN-17-P113	Concurrent hemoperfusion and hemodialysis in patient with acute pesticide intoxication	Sae-Yong Hong
KSN-17-P179	Mucoadhesive nanospheres based ocular delivery of insulin	Aakanchha Jain
KSN-17-P180	Intranasal delivery of insulin for the restoration of memory signaling in Alzheimer disease	Vishal Bhargava
KSN-17-P181	PEGylated glucose triggered liposomes for insulin delivery	Sourabh Jain
KSN-17-P182	Prevention of ocular morbidity in diabetic chronic kidney disease with respect to correction of anemia	Pranita Chaudhary
KSN-17-P311	Angiotensin II-mediated MYH9 down-regulation causes structural and functional podocyte injury in diabetic kidney disease	Jeong Suk Kang
KSN-17-P314	Recalibration and validation of the Charlson comorbidity index in Asian population: the National Health Insurance Service-National Sample Cohort study	Jae Shin Choi

Dialysis		
Presentation No.	Title	Presenting Author
KSN-17-P079	Relationship between fatigue and body composition parameters measured by bio impedance analysis in hemodialysis patients	Jong Hwan Jung
KSN-17-P080	The effect of education program for taking phosphate binders on the self-efficacy, phosphate-related knowledge, medication adherence, and physiological index in hemodialysis patients with hyperphospha	Kwi Kyung Kim
KSN-17-P081	The effect of continuous hemodiafiltration on the pharmacokinetics of maintenance doses of teicoplanin	Inwhee Park
KSN-17-P082	Predictive value of cystatin C-based GFR for successful weaning from continuous renal replacement therapy: a prospective observational study	Chang Seong Kim

Presentation No.	Title	Presenting Author
KSN-17-P083	The prevalence and clinical interpretation of pyuria in end-stage renal disease patients	Hye Min Choi
KSN-17-P084	Two cases of spontaneous renal hemorrhage in hemodialysis patients	Boram Cha
KSN-17-P085	The prevalence of fabry disease in hemodialysis patients of Jeju island	So Mi Kim
KSN-17-P086	Individualized prediction of mortality using multiple inflammatory markers in patients on dialysis: a prospective multicenter cohort study	Hee-Yeon Jung
KSN-17-P087	Relation between different blood pressure measurements and left ventricular hypertrophy in peritoneal dialysis patients	Yun Jung Oh
KSN-17-P088	The association of comorbidities with adverse outcomes during pre-dialysis periods among incident renal replacement therapy patients	MinJeong Lee
KSN-17-P089	Prolonged catheter use as a bridge to AVF or AVG does not affect patient's survival	Hoon Suk Park
KSN-17-P090	Hemodiafiltration is associated with better patients' survival compared with conventional hemodialysis	Hoon Suk Park
KSN-17-P091	Comparison of patients' survival between AVG and catheter as a permanent hemodialysis vascular access	Hoon Suk Park
KSN-17-P092	Ultra sonographic assessment of anatomical variations of internal jugular vein in patients undergoing hemodialysis catheter placement	Srikanth Prasad
KSN-17-P093	Safety of erythropoietin administration among End-stage renal disease patients	Jong hoon Lee
KSN-17-P094	Circulating cell-free genomic DNA, mitochondrial DNA and pentraxin-3 in the patients on hemodialysis and medical staffs during isolation by Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in K	Yang Gyun Kim
KSN-17-P095	Chordae rupture and acute mitral regurgitation associated with infective endocarditis in a hemodialysis patient	Bomi Choi
KSN-17-P096	Development of an ultrasonography-guided puncture simulator: second report	Hiroshi Sakurai
KSN-17-P097	Two cases of adhesiolysis as an effective treatment for encapsulating peritoneal sclerosis after kidney transplantation	Ha Yeon Park

Presentation No.	Title	Presenting Author
KSN-17-P098	Clinical characteristics of patients with long-term continuous ambulatory peritoneal dialysis	Ha Yeon Park
KSN-17-P099	The effect of selenium deficiency on cardiovascular diseases in peritoneal dialysis patients	Hyemi Seo
KSN-17-P100	Changes of bio impedance and segmental body composition measurement value before and after hemodialysis in end stage renal disease patients	Hyunsuk Kim
KSN-17-P101	Eight years survival rate of on-line hemodiafiltration	Jung Hwan Yoon
KSN-17-P102	Changes of hemoglobin level and erythropoietin stimulating agent dose after mid-week predialysis blood sampling	Soo Ya Bae
KSN-17-P103	B-type natriuretic peptide is a good biomarker for the treatment of hypertension in children with end-stage renal disease on peritoneal dialysis	Joo Hoon Lee
KSN-17-P104	Real-world treatment pattern of renal anemia in hemodialysis patients: a multicenter cohort study using dialysis net	Kyung Don Yoo
KSN-17-P105	The effects of substitution of acetate dialysate by citrate dialysate in central delivery hemodialysis system: a retrospective observational study	Eun Ji Park
KSN-17-P106	Volume overload is associated with increased mortality in peritoneal dialysis patients	Jin Joo Cha
KSN-17-P107	The change of peritoneal protein clearance is an independent risk factor for predicting mortality in a large cohort of PD patients with peritonitis	Kyoung Sook Park
KSN-17-P108	The usefulness of automated blood culture method to detect causative organisms causing peritonitis in PD patients: long-term validity assessment about replacement of conventional culture method	Ea Wha Kang
KSN-17-P109	Factors affecting peritonitis and mortality in PD patients	TaeYeon Hwang
KSN-17-P110	High glucose exposure from peritoneal dialysis fluid is associated with all-cause mortality and dialysis failure in patients undergoing peritoneal dialysis	Joohwan Kim
KSN-17-P111	Interval change plasma neutrophil gelatinase-associated lipocalin level and urine output as a predictor for survival in critically ill patients undergoing continuous renal replacement therapy	Ha Yeon Kim
KSN-17-P112	The spontaneous rupture of contracted kidney with renal hematoma in patients on CAPD: five cases in Inha University kidney center between years 1996 - 2016	Moon-Jae Kim

Presentation No.	Title	Presenting Author
KSN-17-P183	Early complications of peritoneal dialysis in pediatric patients in Kazakhstan	Marina Khvan
KSN-17-P236	The recovery of peritoneal-pleural leak by modality-change of peritoneal dialysis in patient undergoing peritoneal dialysis	Jee Eun Choi
KSN-17-P237	Spontaneous retroperitoneal hemorrhage caused by renal cyst rupture in an ACKD peritoneal dialysis patient: a case report	Young Moon Kim
KSN-17-P238	Effect of hemoperfusion with deferoxamine administration on ferritin levels in a thalassemia patient with iron overload	Samel Park
KSN-17-P239	Increased risk of mortality and major cardiovascular adverse events, major bleeding outcomes associated with non-steroidal anti-inflammatory drugs (A nationwide case-crossover study)	Hyung Ah Jo
KSN-17-P240	Automated peritoneal dialysis-related peritonitis caused by co-infection with <i>Morganella morganii</i> and <i>Corynebacterium</i> species	Kyeong Min Kim
KSN-17-P241	The Effect of 12 months- continuous positive airway pressure therapy on cognitive function, sleep, mood and health-related quality of life	Ea Wha Kang
KSN-17-P242	Death risks over time from 2001 to 2015 in incident peritoneal dialysis patients: a retrospective cohort study with 15-year follow-up	Min Ji
KSN-17-P243	Effect of oral vitamin D treatment on peritoneal membrane function in patients with peritoneal dialysis	Ho Lee
KSN-17-P244	Open surgical continuous ambulatory peritoneal dialysis catheter implantation operation; Interventional nephrologist vs surgeon: a comparative, single center study	Jin Ho Lee
KSN-17-P245	A case of troca-induced small bowel trauma and catheter malfunction in patients who was underwent PD catheter implantation operation	Jin Ho Lee
KSN-17-P246	The prediction of clinical outcome in diabetic patients with continuous renal replacement therapy: focusing HbA1c	Inseong Park
KSN-17-P247	Low Parathyroid hormone levels predict with infection-related mortality in incident dialysis patients	Yu Ah Hong
KSN-17-P248	The impact of early hospitalizations after initiation of dialysis on all-cause mortality in incident hemodialysis patients	Yu Ah Hong
KSN-17-P249	Association of serum uric acid level and coronary artery stenosis severity in end stage renal disease patients	Hye Yun

Presentation No.	Title	Presenting Author
KSN-17-P250	Mortality outcomes for incident dialysis patients with mental or physical disabilities according to dialysis modality: a national population-based study in Korea	Donghwan Oh
KSN-17-P251	The pattern of choosing dialysis modality and related mortality outcomes in Korea: interaction analysis between comorbid conditions and dialysis modality	Donghwan Oh
KSN-17-P252	Cumulative fluid balance and mortality in elderly patients with acute kidney injury requiring continuous renal replacement therapy: a multicenter prospective cohort study	Jong hyun Jhee
KSN-17-P253	Monitoring volume status using bioelectrical impedance analysis in chronic hemodialysis patients	Jung-ho Shin
KSN-17-P254	Association between vascular calcification and residual renal function in patients on hemodialysis with urination	Jong-woo Yoon
KSN-17-P255	Medical utilization and personal out-of-pocket medical expenditure according to the subtype of medical social security in end stage renal disease	Sun Mi Shin
KSN-17-P256	Prediction of hemodialysis vascular access failure using data from segmental bioimpedance analysis	Hye Mi Seo
KSN-17-P257	A case of pheochromocytoma in a patient with hemodialysis	Ji Young Kim
KSN-17-P258	Successful treatment of acquired perforating dermatosis in a patient on peritoneal dialysis by using oral isotretinoin	Huiseo Kim
KSN-17-P259	Effect of sorafenib on epithelial to mesenchymal transition of peritoneal mesothelial cells	Joon Hyuk Seo
KSN-17-P260	Assessment of dialysis adequacy by ultraviolet absorbance: comparison to standard method of urea removal	Heo Jung Yoon
KSN-17-P261	Single-center experience of tunneled hemodialysis catheter insertion without fluoroscopy	Kyu Hyang Cho
KSN-17-P262	Muscle mass measured by multi-frequency bioimpedance and intradialytic hypotension among hemodialysis patients	Jong Cheol Jeong

Fluid, Electrolyte and Acid-Base		
Presentation No.	Title	Presenting Author
KSN-17-P073	Prediction of hyponatremia using deep learning approach with Ensemble model from EMR	Sug Kyun Shin
KSN-17-P074	The additive value of serum anion gap and pH for mortality in patients receiving concomitant continuous renal replacement therapy and extracorporeal membrane oxygenation	Jin Hyuk Paek
KSN-17-P075	A case of parathyroid adenoma presented as recurrent pancreatitis	Jihyun Yang
KSN-17-P076	The clinical benefit of bio impedance body composition measurement on correction of hypernatremia	Seul-gi Kim
KSN-17-P263	Severe hypokalemic paralysis in a young bodybuilder	Tae Won Lee
KSN-17-P264	Continuous renal replacement therapy as a treatment for severe acute hypernatremia induced by central diabetes insipidus	Kitae Kim
KSN-17-P265	Renal expression of ammonia transporters in response to angiotensin II receptor blocker in the rat with chronic kidney disease	Seung Jung Kim
Geriatric Nephrology		
Presentation No.	Title	Presenting Author
KSN-17-P077	Acute pyelonephritis patients older than 75 years: characteristics and factors associated with prolonged hospitalization or mortality	Jung Hwan Park
KSN-17-P078	Harmful effect of low skeletal muscle mass on the long term patient survival in the elderly acute kidney injury patients who underwent continuous renal replacement therapy	Harin Rhee
Glomerular & Tubulointerstitial Disease		
Presentation No.	Title	Presenting Author
KSN-17-P114	Differentiation of dysmorphic RBC by automated urine analyzer UF-1000i system	Seyoung Bahk
KSN-17-P115	Clinical value of urinary cytokines / chemokines as prognostic markers in patients with crescentic glomerulonephritis	Jeeun Park
KSN-17-P116	Febuxostat inhibits ER stress and renal fibrosis through activation of SIRT1, followed by induction of AMP-activated protein kinase, heme oxygenase-1, and thioredoxin	Hyosang Kim

Presentation No.	Title	Presenting Author
KSN-17-P117	ANCA-associated vasculitis with both MPO-ANCA and PR3-ANCA shares characteristics of ANCA-associated vasculitis with single ANCA	Sun Moon Kim
KSN-17-P118	Clinical characteristics in elderly patients aged over 65 years with biopsy-proven kidney diseases	Woo Yeong Park
KSN-17-P119	Long-term outcome and possible prognostic factors of childhood IgA nephropathy in a multi-center study in Korea	Kyung-Mi Jang
KSN-17-P120	Exogenous CGRP upregulates profibrogenic growth factors through PKC and JNK signaling pathway in kidney proximal tubular cells	Daeun Moon
KSN-17-P121	The possibility of renal regeneration by prostaglandin in IgA nephropathy and FSGS	Sihyung Park
KSN-17-P122	Correlation of renal echogenicity with renal pathology and function	Jinhee Lee
KSN-17-P123	Renal biopsy at OPD level	Hyaejin Yun
KSN-17-P124	Short-term anti-proteinuric effect of tacrolimus is not related to preservation of glomerular filtration rate during 5 year-follow up period in IgA nephropathy	Mi-yeon Yu
KSN-17-P125	A case of lupus nephritis in twin sister	Sangmok Yeo
KSN-17-P126	Loss of KLF15 promotes chronic podocyte injury	Seung Seok Han
KSN-17-P127	Clinical outcomes and effects of treatment in older patients with idiopathic membranous nephropathy	Yaeni Kim
KSN-17-P184	Genetic variants of IL-1R1 and IL-1R2 genes and IgA nephropathy risk in the Han Chinese population	Maowei Xie
KSN-17-P185	Association of podocyte autophagosome numbers with idiopathic membranous nephropathy and secondary membranous nephropathy	Juan Jin
KSN-17-P267	Allo- peripheral blood stem cell transplantation induced membranous nephropathy as chronic GVHD	Inwhee Park
KSN-17-P268	Focal segmental glomerulosclerosis associated with polycythemia progressed to chronic renal failure in 16-year-old boy with severe obesity	Kyung-mi Jang
KSN-17-P269	Heavy proteinuria in a child with single ventricle	Aram Kwon
KSN-17-P270	Biopsy proven obesity related glomerulopathy(ORG)	Sung Min Kwon

Presentation No.	Title	Presenting Author
KSN-17-P271	Light chain deposition disease associated with multiple myeloma during pregnancy	Min Jeong Kim
KSN-17-P272	Serum growth differentiation factor-15 predicts renal outcome in idiopathic membranous nephropathy	Youngrok Ham
KSN-17-P273	Pattern of glomerular disease diagnosed by renal biopsy	Sang Mi Park
KSN-17-P274	A case of SLE and ANCA associated vasculitis overlap syndrome	Seong Heon Kim
KSN-17-P275	Analysis of native kidney biopsy at one single center	Weon Hyung Lee
KSN-17-P276	Prognostic significance of proteinuria in patients with IgA nephropathy in a single center study	Yire Kim
KSN-17-P277	C3 glomerulonephritis treated with cyclophosphamide and prednisolone: a case report	Sanghee Lee

Hypertension and Vascular Biology

Presentation No.	Title	Presenting Author
KSN-17-P128	High leucine-rich repeat-containing 17 level is an independent factor for vascular calcification in high cardiovascular risk patients	Cheol Ho Park
KSN-17-P129	Coronary artery calcification predicts arterial microcalcification in nondiabetic hemodialysis patients	Bomi Choi
KSN-17-P130	Physicians' perception of blood pressure control in patients with chronic kidney disease and the achievement rate of target BP based on the AProDiTe-2 study	Ran-hui Cha
KSN-17-P131	Increased neutrophil extracellular trap (NET) formation in uremia is associated with chronic inflammation and prevalent coronary artery disease	Jwa Kyung Kim
KSN-17-P132	Clinical significance of heart rate variability monitoring in end-stage renal disease patients	Ji-Yeun Chang
KSN-17-P133	Renin inhibition alleviates doxorubicin-induced nephrotoxicity by inhibiting oxidative stress and podocyte injury	Abul kalam Najmi
KSN-17-P186	Risk of incident stroke in patients with primary aldosteronism: a nationwide population-based study	Yu-hsing Chang
KSN-17-P278	Ipsilateral focal segmental glomerulosclerosis after renal angioplasty on the single functioning kidney in a patient with both renal artery stenosis	Hee Jung Park
KSN-17-P279	Midterm measurement of cystatin C predicts preeclampsia	Sehoon Park
KSN-17-P280	Predictors of predialysis blood pressures over time in patients receiving maintenance hemodialysis	Sinae Lee

Inherited Kidney Disease (Pediatric Nephrology)		
Presentation No.	Title	Presenting Author
KSN-17-P134	Kidney disease progression and clinical outcomes in patients with autosomal dominant polycystic kidney disease	Seong Sik Kang
KSN-17-P135	A case of localized cystic disease of the kidney	Yaerim Kim
KSN-17-P187	Estimation of renal growth adequacy in children with congenital solitary kidney	Linshien Fu
KSN-17-P188	Pseudohypoaldosteronism type 1 in a neonate presenting with acute kidney injury, life-threatening Hyperkalemia and positive family history	Nagasudheerkumar Mekala
KSN-17-P281	Hypokalemic alkalosis in two patients with klinefelter or russel-silver syndrome	Se Jin Park
KSN-17-P282	A case of gitelman syndrome presenting with short stature	Jin-Soon Suh
KSN-17-P283	A novel frameshift mutation found in the Korean family with lecithin-cholesterol acyltransferase (LCAT) deficiency	Hayne Park

Interventional Nephrology

Presentation No.	Title	Presenting Author
KSN-17-P136	Clinical experiences of banding technique on high flow vascular access, arm swelling and steal syndrome	Seong Cho
KSN-17-P137	Efficacy of the ultrasound dilution technique in the surveillance of vascular access in hemodialysis patients	Woo Yeong Park
KSN-17-P138	A single center's experience of vascular access monitoring by hemodilution method	Bong Soo Park
KSN-17-P139	Prediction for maturation of arteriovenous fistula by vascular ultrasonography	Jae Seok Kim
KSN-17-P284	Stenting at migrated stent	Jin Ho Lee
KSN-17-P285	High recirculation rates indicate vascular stenosis in hemodialysis vascular access	Ji-Yeun Chang
KSN-17-P286	Predictive factors for fistula survival in an immature fistula group: a single-center study	Chang Hun
KSN-17-P287	A meta-analysis of randomized clinical trials blood flow and stenosis surveillance of hemodialysis access	Seon Deok Hwang
KSN-17-P288	Bone morphogenetic protein-9 (BMP-9) inhibits HMGB1-induced Endothelial-to-Mesenchymal Transition (EndMT) in human umbilical vein endothelial cells	Jeong-Sun Han

Nephrology Education		
Presentation No.	Title	Presenting Author
KSN-17-P140	Uncontrolled use of antibiotics in the treatment of uncomplicated urinary tract infections by Albanian community pharmacists	Edmond Pistja

Nutrition, Inflammation and Metabolism		
Presentation No.	Title	Presenting Author
KSN-17-P141	Severe vitamin D deficiency is a risk factor for renal hyperfiltration	Jong Hyun Jhee
KSN-17-P142	Metabolically healthy obesity is associated with incident chronic kidney disease in the general population	Hae-Ryong Yun
KSN-17-P143	Metabolically healthy obesity is not healthy and associates with the progression of chronic kidney disease	Hae-Ryong Yun
KSN-17-P144	Effect of cooked food with stir-fried olive oil or not on erythrocyte membrane fatty acid contents in hemodialysis patients	Da Ye Yoon
KSN-17-P145	The discrepancy in the predictability of subjective global assessment (SGA) for mortality according to dialysis modalities	Ye Eun Ko
KSN-17-P146	Comparison analysis for detection of nutritional status using nutritional scores (GNRI and CI) in hemodialysis patients	Wonsun Hwang
KSN-17-P147	Persistent organic pollutants are associated with chronic kidney disease	Hyang Ki Min
KSN-17-P148	Clinical usefulness of unenhanced CT in APN	Anna Lee
KSN-17-P149	The additional benefit of weighted subjective global assessment (SGA) for the predictability of mortality in Korean incident peritoneal dialysis patients	Taeyoung Yun
KSN-17-P150	Validation of handgrip strength as a nutritional assessment tool for maintenance hemodialysis patients in Dr. Sardjito hospital Indonesia	Khoirun Nisa Alfitri
KSN-17-P151	Association between hemodialysis vintage and nutritional status based on anthropometry, physical, and dietary assessment in maintenance hemodialysis patients in Dr. Sardjito hospital Indonesia	Susetyowati Susetyowati
KSN-17-P152	Comparison of simple nutrition screening tool and nutritional risk screening 2002 with subjective global assessment and dialysis malnutrition score for maintenance hemodialysis patients in Dr. Sardjito	Farah Faza


Presentation No.	Title	Presenting Author
KSN-17-P189	Nutrition care process and nutrition status within end stage renal disease undergoing hemodialysis patient	Triyani Kresnawan
KSN-17-P289	Comparison of the urine sodium excretion estimates derived from spot urine and measured 24hr urine sodium in renal disease patients – Correlation analysis according to voiding time	Yongjin Yi
KSN-17-P290	Predicting clinical outcomes using phase angle as assessed by bioelectrical impedance analysis in maintenance hemodialysis patients	Jung-ho Shin
KSN-17-P291	Serum zinc level as a chronic inflammation marker in patients with chronic kidney disease	Minyoung Kim
KSN-17-P292	Pediatric urinary tract infections caused by extended-spectrum beta-lactamase-producing bacteria	Hye Sun Hyun

Transplantation		
Presentation No.	Title	Presenting Author
KSN-17-P153	Factors associated with negative attitudes toward organ donation among Moroccan university students	Hajar Ellassas
KSN-17-P154	Estimating donor organ quality with baseline histology and kidney donor risk index for predicting graft outcomes in deceased donor kidney transplantation	Kyung Sun Park
KSN-17-P155	Conversion from calcineurin inhibitor to sirolimus in kidney transplantation recipients with malignancy	Jung A Yoon
KSN-17-P156	Experience of pediatric kidney transplantation between 1985 and 2016: a single regional center study	Hee Sun Baek
KSN-17-P157	Urinary proteomic biomarkers discovery for prediction of acute rejection in kidney transplant recipients	Hee-Yeon Jung
KSN-17-P158	Kidney donor risk index is a good prognostic tool for prediction of early post-transplant kidney function and graft survival in Korean population	Han Ro
KSN-17-P159	Extracellular fluid excess is significantly associated with coronary artery calcification in kidney transplant recipients	Seohyun Park

Presentation No.	Title	Presenting Author
KSN-17-P160	Effect of conversion to belatacept on tacrolimus-induced diabetes mellitus in rats	Long Jin
KSN-17-P161	Dehydropeptidase-I inhibitor reduces tacrolimus-induced kidney injury by anti-oxidative and anti-apoptotic effect	Kang Luo
KSN-17-P162	Identification of urinary biomarkers for recurrence of IgA nephropathy after kidney transplantation using proteomic methods	Hee Jung Jeon
KSN-17-P163	BK Virus Infection in pediatric kidney allograft recipients: experience of a referral center in Korea	Young Hoon Cho
KSN-17-P164	Pre- and post-transplant serum alkaline phosphatase predicts graft failure and mortality in kidney transplant recipients	Yong Chul Kim
KSN-17-P165	An observational study for non-invasive detection of tacrolimus toxicity and graft injury using urine cellular RNA expression in kidney transplantation	Jungwoo Seo
KSN-17-P166	How to promote regeneration after ischemic reperfusion injury: dual role of CD 137 agonistic antibody	Jong Soo Lee
KSN-17-P167	A case of delayed graft function in the kidney transplant	Hyun Woo Kim
KSN-17-P168	Successful treatment with octreotide on lymphorrhea after kidney transplantation	Sun Ae Han
KSN-17-P169	Detection of pre-transplant donor specific antibodies in living related renal allograft transplant and its clinical significance: a single centre experience	Monika Jain
KSN-17-P170	Outcomes of end-stage renal disease patients on waiting list for deceased donor kidney transplantation- single center study	Hong Jae Jeon
KSN-17-P171	The renal allograft function is a risk factor of left ventricular remodeling after kidney transplantation	Tai Yeon Koo
KSN-17-P172	Long-term outcomes of steroid withdrawal between 3 and 6 months after kidney transplantation with induction therapy and tacrolimus and mycophenolate mofetil	Subin Hwang
KSN-17-P190	Kidney transplantation in a patient with CDC positive crossmatch, negative flow cytometry crossmatch and donor specific antibody	Swati Agrawal


Presentation No.	Title	Presenting Author
KSN-17-P191	FcyRIIb expression on B cells is associated with treatment efficacy for acute rejection after kidney transplantation	Juan Jin
KSN-17-P293	Treatment of acute rejection in hiv-infected patients undergoing kidney transplantation	Jin Won Jang
KSN-17-P294	UVJ stenosis in KTP: ballooning	Jin Ho Lee
KSN-17-P295	An open-label, single-arm study assessing efficacy of sirolimus based immunosuppression in the renal transplant patient with fibroadenoma	Min Ji Kim
KSN-17-P296	Pre-transplant malignancy on kidney transplant recipients is not associated to the incidence of post-transplant malignancy	Tae Hyun Ban
KSN-17-P297	Hemodialysis catheter-related right atrial thrombus detected prior to kidney transplantation	Soomin Jeung
KSN-17-P298	A case of desensitization, transplantation, and early antibody mediated rejection in a negative flow cross-match and pretransplant donor-specific antibody	Yong Hun Sin
KSN-17-P299	Impact of the baseline anti-A/B antibody titer in ABO-incompatible living kidney transplantation	Yong Hun Sin
KSN-17-P300	Clinical usefulness of lymphocyte subset analysis for the prediction of acute rejection in kidney transplant recipients	Ji-Won Min
KSN-17-P301	Anti-HLA antibody-mediated rejection in ABO-incompatible(ABOI) living donor kidney transplant (KT) patients	Sung hyun Son
KSN-17-P302	Prediction of the clinical outcomes after deceased donor kidney transplantation using kidney donor profile index	Woo Yeong Park
KSN-17-P303	Risk factors affecting clinical outcome in contemporary kidney transplantation; single center experience	Jae Sung Ahn
KSN-17-P304	Allograft crescent predicts graft failure in recurrent IgA nephropathy patients	Sehoon Park
KSN-17-P305	Improvement of left ventricular diastolic function after kidney transplantation	Kyung Sun Park
KSN-17-P306	Remission psoriasis after kidney transplantation	Hee Yeoun Kim
KSN-17-P312	Clinical significance of CD161+ lymphocyte in chronic antibody mediated rejection in kidney transplant recipients	Ji-Won Min

Convention Centre 4F




1~2	Roche Korea
3~4	FMC Korea
5~6	JW Pharmaceutical
7~8	Otsuka Pharmaceutical
9~10	Kyowa Hakko Kirin Korea
11~12	SK Chemicals
13~14	Boryung
15~16	CJ Healthcare
17~18	Baxter

Convention Centre 3F



1~2	Sanofi-Aventis Korea
3~4	MSD Korea
5~6	Sanofi Genzyme
7~8	Yuhan co.
9~10	Alvogen
11~12	Daewon
13~14	HANDOOK
15~16	Novartis


Convention Centre 1F



1	B. Braun Korea
2	SeMyeong Medical Device Corp
3~4	Asahi Kasei Medical Trading (Korea) Co., LTD
5~6	Abbvie
7	Servier Korea
8	WS Medical.Co.,Ltd
9~10	Hanmi Pharm. Co., Ltd.
11	Medtronic Korea
12	Boehringer Ingelheim
13	Daiichisankyo Korea Co.,LTD
14	BMVITEK
15	Green Cross
16	Bayer Korea
17~18	Astellas
19	Shire Pharma Korea
20~21	Chong Kun Dang pharmaceutical Corp

Registration Desk Operation time

Date	Time	Location
May 18 (Thu)	12:00 - 16:30	Convention Centre 4F Lobby
May 19 (Fri)	07:30 - 16:00	
May 20 (Sat)	07:30 - 16:30	
May 21 (Sun)	07:30 - 11:00	



Sponsors

Platinum



Gold



Silver




KSN 2017

Seoul, Korea · May 18 - 21


KSN 2017

Seoul, Korea · May 18 - 21

전문약품
분류번호 392 : 해독제



“캡슐 복용으로
활짝 웃습니다.”



캡슐형 투석지연제

레나메진


(구형흡착탄)



캡슐제형의
투석지연제



후대가 편리한
파우치 포장



1회 2g을 약물 손실
없이 모두 복용



국산원료, 국내생산



daewon 대원제약주식회사 (우)04808 서울특별시 성동구 천호대로 386 TEL: (02)2204-7000, (수신자부담) 080-497-8272 FAX: (02)498-9108
Website: www.daewonpharm.com *보다 자세한 내용은 제품설명서 및 홈페이지를 참조하세요.

SANOFI

Before you start, stop.

Because the benefits should accumulate. Not the risks.


Renvela® is an effective first-line monotherapy for controlling serum phosphorus in dialysis patients - without calcium or metal¹ accumulation. Sevelamer shows a 46% reduction in all-cause mortality compared with CBBs for CKD patients.²





Renvela tab. (Sevelamer carbonate) Renvela powder 0.8g (Sevelamer carbonate) Composition Active ingredient Sevelamer Carbonate 800mg (K-House Monograph) **Indications** The control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. **Dosage and Administration** Renvela should be given three times a day with meals. Mix one sachet in at least 30mL of water. Must be administered within 30 minutes of meals, and resuspended before administration. **Patients Not Taking a Phosphate Binder** The recommended starting dose of Renvela is 0.8 to 1.6 g with meals, based on serum phosphorus level. Serum phosphorus level 5.0 ~ 7.5 mg/dL : 1 sachet/sachet three times daily with meals. Serum phosphorus level 7.5 ~ 10.0 mg/dL : 2 sachet/sachet three times daily with meals. **Switching from Sevelamer Hydrochloride Tablets** For patients switching from sevelamer hydrochloride tablets to sevelamer carbonate tablets or powder, use the same dose in grams. Further titration may be necessary to achieve desired phosphorus level. The highest daily dose of sevelamer carbonate studied was 14 grams in CKD patients on dialysis. **Switching from Sevelamer Carbonate tablets to sachets or from sachets to tablets** For patients switching from sevelamer carbonate tablets to sevelamer carbonate sachets, use the same dose in grams. Further titration to the desired phosphorus level necessary to achieve desired phosphorus level. **Switching from Calcium Acetate** Calcium Acetate 667 mg/1 tablet three times daily, 1 tablet or sachet three times daily, Calcium Acetate 667 mg/2 tablets three times daily, 2 tablets or sachets three times daily, Calcium Acetate 667 mg/3 tablets three times daily, 3 tablets or sachets three times daily. **Dose Titration for All Patients Taking Renvela** Titrate the Renvela dose by 0.8 g three times per day with meals at two-week intervals as necessary with the goal of controlling serum phosphorus within the target range. **Contraindication** Hypersensitivity to the active substance or to any of the excipients. **Precaution** Patient taking bowel obstruction. There is a risk of bowel obstruction and perforation due to swelling in intestinal. **Adverse reactions** In a study in hemodialysis patients, the adverse reactions on sevelamer carbonate powder were similar to those reported for sevelamer hydrochloride. In another crossover study in hemodialysis patients, the adverse reactions on sevelamer carbonate powder were similar to those reported for sevelamer hydrochloride. In a study of sevelamer hydrochloride, overall adverse reactions among those treated with sevelamer hydrochloride occurring in 1% of patients included: vomiting (22%), nausea (20%), diarrhea (19%), dyspepsia (16%), abdominal pain (9%), flatulence (8%) and constipation (8%). In a study for peritoneal dialysis patients using sevelamer hydrochloride, most adverse reactions were similar to adverse reactions observed in hemodialysis patients. The following adverse reactions have been identified during post-marketing use of sevelamer hydrochloride, which has the same active moiety as sevelamer carbonate: pruritus, rash, abdominal pain, local irritation, and uncommon cases of liver, intestinal obstruction, and intestinal perforation. Appropriate medical management should be given to patients who develop constipation or have worsening of existing constipation to avoid severe complications. For more details, please refer to the product package insert.

Reference 1: Renvela FDA label revised March 2016 2: Patel L et al. Clin J Am Nephrol 2016 ;11(2):232-244

Renvela
sevelamer carbonate
Right from the start™



MANATHAN[®] INJ.
Nafamostat mesilate 10mg / 50mg



150-945 13F. TWO IFC Bldg. 10 Gukjegeumyung-ro, Yeongdeungpo-gu, Seoul, Korea
TEL : +82-2-2047-7700 | Customer Service : 080-729-5800 | infokorea@alvogen.com



듀오웰은
텔미사르탄 및 로수바스타틴칼슘 복합제로
고혈압, 고지혈증을 간편하게
동시에 치료할 수 있는 지름길입니다.

[illegible]

DIAB-1188707-0012 09/2018

Soliris® (eculizumab)

Inhibits complement-mediated TMA and the devastating consequences of aHUS^{1, 2}

Selected Prescribing Information

[제품명] 솔리리스® 주 (성분-활량) 1 바이알(30mL) 중 주성분 : 에쿨리주맙(병규) 300mg **[성상]** 무색투명한 액이 무색투명한 바이알에 든 주사제 **[효능·효과]** 1) 발작성 야간 혈색소뇨증(PNH) : Paroxysmal Nocturnal Hemoglobinuria; 용혈을 감소시키기 위한 발작성 야간 혈색소뇨증 환자의 치료. 수혈 이력과 관계없이, 높은 질병 활성을 의미하는 임상 증상이 있는 환자의 용혈에 임상적 이익이 확립되었다. 2) 비정형 용혈성 요독 증후군(aHUS : atypical Hemolytic Uremic Syndrome): 보체 매개성 혈전성 미세혈관병증을 억제하기 위한 비정형 용혈성 요독 증후군 환자의 치료 **[용법·용량]** 심각한 감염에 대한 위험을 줄이기 위해서 환자들은 최선의 백신 접종 지침(Advisory Committee on Immunization Practices(ACIP) recommendations)에 따라 백신 접종을 해야 한다. 침묵균에 감염되어 있다. **[면역항응응]** 발작성 야간 혈색소뇨증(PNH) - 첫 4주간은 매 7일마다 600 mg을 투여한다. - 네 번째 용량 투여 7일 후에 다섯 번째 용량으로 900 mg을 투여하고, - 그 후부터는 매 14일마다 900 mg을 투여한다. 이 약은 권장 투여량과 일정에 맞게 투여, 혹은 예정된 일정의 2일 전/후로 투여 되어야 한다. 비정형 용혈성 요독 증후군(aHUS) 만 18세 이상의 한자일 경우, - 첫 4주간은 매 7일마다 900 mg을 투여한다. - 네 번째 용량 투여 7일 후에 다섯 번째 용량으로 1200 mg을 투여하고, - 그 후부터는 매 14일마다 1200 mg을 투여한다. **[주요 사용상의 주의사항]** 경고: 중대한 수막염균 감염 작용기전으로 인하여 이 약의 사용은 중대한 수막균 감염(매일 중 그리고/또는 뇌수막염에 대한 환자의 감수성을 증가시킨다. 이 약의 투여 환자에서 치명적이고 생명을 위협하는 수막균 감염이 발생하였다. 수막균 감염은 어느 혈청군에 의해서도 발생할 수 있지만, 이 약의 투여 환자들은 흔하지 않은 혈청군(X 등)에 의한 질환이 발생할 수 있다. 보체 결핍 환자는 최선의 백신 접종 지침에 따라 다가가 수막균 백신을 접종 받아야 하며, 이 약의 치료 기간을 고려하여 최선의 백신 접종 지침(Advisory Committee on Immunization Practices(ACIP) recommendations)에 따라 백신 접종을 받아야 한다. 다음 환자에는 투여하지 말 것 1) 이 약의 주성분, 무관 단백질 또는 기타 구성성분에 과민반응이 있는 환자 2) 치료되지 않은 중대한 수막균 뇌수막염(Neisseria meningitidis) 감염 환자 3) 수막균 뇌수막염(Neisseria meningitidis) 백신을 현재 접종하지 않은 환자 또는 백신 접종 이후 2주 동안 적절한 예방적 항생요법으로 치료를 받지 않은 환자(이 약의 치료를 늦추는 것이 수막균 감염을 일으키는 것보다 중대하지 않은 경우). **[저장방법]** 일용용기, 차광하여 냉장(2~8°C)보관. 얼리지 말 것. **[제조원]** 일렉시온 **[수입·판매원]** ㈜한독 ※보다 자세한 정보는 제품설명서를 참조하시기 바랍니다.

References

1. Soliris Europe Product Information (as of 2016.10.06) 2. Legendre CM, Licht C, Muus P, et al. N Engl J Med. 2013;368:2169-2181.

ALEXION

※ 한독 서울특별시 강남구 테헤란로 132 Tel.02)527-5114 Fax.02)527-5001 www.handok.co.kr

HANDOK

Nifedipine 40mg Controlled release

Niferon 40

Formulation Technology

미국, 유럽 제형특허 제품입니다.

Evidence of Efficacy and Safety

스위스, 독일, 덴마크 등에서 10년 이상 처방된 제품입니다.



Actual Size

제조원 **에리슨제약(주)**

판매원 **KPP (주)경풍약품**

원료공급 및 기술제휴 Siegfried Ltd., Switzerland



선생님, 정말 감사합니다!

제2형 당뇨병 환자를 위한 새로운 SGLT2 억제제*

자디앙®은 성인 제 2형 당뇨병환자의 혈당 조절을 향상시키기 위해 식이요법 및 운동요법의 보조제로 투여합니다.

- 1 이 약은 단독요법으로 투여합니다.
- 2 메트포르민 단독요법으로 충분한 혈당 조절을 할수 없는 경우, 이 약을 병용투여합니다.
- 3 메트포르민과 피오글리타존 병용요법, 또는 메트포르민과 설폰닐우레아 병용요법으로 충분한 혈당조절을 할수 없는 경우, 이 약을 병용투여합니다.
- 4 인슐린 (인슐린 단독 또는 메트포르민 병용 또는 메트포르민과 설폰닐우레아 병용) 요법으로 충분한 혈당 조절을 할수 없는 경우, 이 약을 병용투여합니다.

SGLT2 = sodium-glucose co-transporter2

자디앙®
(엠파글리플로진)

Jardiance®
(empagliflozin)

Reference 1. 자디앙® 식약처 허가사항, 2014.

Prescribing Information

자디앙®정 (엠파글리플로진) ■ 원료약품 및 분량 자디앙정 10 mg (엠파글리플로진) 1정(257.0 mg) 중 주성분 : 엠파글리플로진 (염구) 10 mg 자디앙정 25 mg (엠파글리플로진) 1정 (206.0 mg) 중 주성분 : 엠파글리플로진 (염구) 25 mg ■ **효능·효과** 이 약은 성인 제 2형 당뇨병 환자의 혈당조절을 향상시키기 위해 식이요법 및 운동요법의 보조제로 투여한다. 1. 이 약은 단독요법으로 투여한다. 2. 메트포르민 단독요법으로 충분한 혈당조절을 할 수 없는 경우, 이 약을 병용투여한다. 3. 메트포르민과 피오글리타존 병용요법, 또는 메트포르민과 설폰닐우레아 병용요법으로 충분한 혈당조절을 할 수 없는 경우, 이 약을 병용투여한다. 4. 인슐린 (인슐린 단독 또는 메트포르민 병용 또는 메트포르민과 설폰닐우레아 병용) 요법으로 충분한 혈당조절을 할 수 없는 경우, 이 약을 병용투여한다. ■ **용법·용량** 이 약의 초기 권장용량은 단독 요법 및 인슐린 등 다른 혈당 강하제의 추가 병용 요법에 대하여 1일 1회 10 mg이다. 이 약 10 mg에 내약성이 우수하면서 추가적인 혈당조절이 필요한 경우, 사구체 여과율 (eGFR)이 60 mL/min/1.73m² 이상인 환자는 이 약 용량을 1일 1회 25 mg으로 증량할 수 있다. 이 약과 설폰닐우레아 또는 인슐린을 병용투여시에는 저혈당 발생의 위험을 감소시키기 위해 설폰닐우레아 또는 인슐린의 용량감소를 고려할 수 있다 (사용상의 주의사항. 3. 이상반응을 참 조). 이 약은 식사와 관계없이 투여할 수 있다. 정제는 통째로 삼켜서 복용한다. 이 약의 복용을 잊었을 때에는 생기는 즉시 복용한다. 하루에 두 배의 용량을 복용하지 않는다. ■ **사용상의 주의사항** 1. 다음 환자에는 투여하지 말 것 1) 이 약의 주성분 및 구성성분에 과민반응이 있는 환자 2) 제 1형 당뇨병 또는 당뇨병성 케톤산증 환자 3) 사구체 여과율 (eGFR)이 30 mL/min/1.73m² 미만인 환자, 말기 신질환 (end stage renal disease) 또는 투석 중인 환자 4) 이 약은 유당을 함유하고 있으므로, 갈락토스 불내성 (galactose intolerance), Lapp 유당분해효소 결핍증 (lapp lactase deficiency) 또는 포도당-갈락토스 흡수장애 (glucose-galactose malabsorption) 등의 유전적인 문제가 있는 환자에게는 투여하면 안 된다. ■ **저장방법** 기밀용기, 실온보관 (1~30°C) ■ **제조사** Boehringer Ingelheim Pharma GmbH & Co. KG, 독일 (Binger Strasse 173, 55216 Ingelheim / Rhein, Germany) ■ **수입자** 한국베링거인겔하임(주), 한국 (서울 중구 통일로 10 연세재단세브란스빌딩 16층)

수입판매인
한국베링거인겔하임(주) | 서울시 중구 통일로 10 연세재단 세브란스 빌딩 16층 (04257)
www.bikr.co.kr TEL : 080-222-0110

공동판매인
한국윌리 | 서울특별시 중구 주암로 98 STX남산타워 4층 (04637)
www.lilly.co.kr



Equip them for the challenging road they travel



- 최대 4.7%의 HbA_{1c} 강하 효과¹
- Glimepiride와 2년 동안 유사한 HbA_{1c} 강하 효과²
- 트라젠티아®는 신장애/간장애에 따른 용량조정 없이 5mg 한 알 투여³

Real evidence of efficacy

아달라트® 오로스는 지난 20년간 다양한 임상시험을 통해 고혈압 환자에 대한 효과와 안전성 프로파일을 입증 해 왔습니다.

- INSIGHT study를 통해, 1일 1회 복용으로 24시간 일정하고 안정된 혈압조절 효과 입증¹

- ACTION study를 통해, 안정형 협심증을 동반한 고혈압 환자에서 장기간(>5년) 혈압강하효과 입증²

- 한국 환자*를 대상으로 실시한 FOCUS study를 통해, 단독 및 병용 요법 모두에서 우수한 혈압조절 효과 입증³

*저용량 항고혈압제 단독요법으로 혈압조절이 어려운 고혈압 환자

트라젠타®정(리나글립틴) 전문약품[illegible]**트라젠타듀오®정(리나글립틴, 메트포르민)** 전문약약품[illegible]

References

1. Mu Y, Pan C, Fan B, et al. Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naïve Asian patients with type 2 diabetes. *Diabetes Res Clin Pract*. 2017;124:48-56. 2. Galkwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. *Lancet*. 2012;380:475-483. 3. Trajenta® 식약처 허가사항. 2016. US PI.

*In the severe hyperglycemia group(n=143), linagliptin 2.5mg/metformin 1000mg bid produced a superior HbA1c reduction(-4.7%) versus linagliptin 5mg qd(-3.5%) after 12 weeks

수업편 한국백령기인결하임주	서울특별시 중구 통일로 10 연세재단 세브란스빌딩 16층 (04527) www.bikr.co.kr TEL : 080-222-0110	 유한은행	서울시 동작로 노랑리 74 www.yuhan.co.kr	공급편 한국물리	서울특별시 중구 후암로 98 STX남산타워 4층 www.lilly.co.kr
-------------------	--	---	-----------------------------------	-------------	---



